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Short summary: A study exploring strategies for scale-up of PrEP for women at population-level 39 
across sub-Saharan African countries spanning a range of HIV burden, weighing individual cost-40 
effectiveness with population impact. 41 
 42 
 43 
Abstract  44 
Objectives: New HIV infections remain higher in women than men in sub-Saharan Africa. PrEP is an 45 
effective HIV prevention measure, currently prioritized for those at highest risk, such as female sex 46 
workers (FSW), for whom it is most cost-effective. However, the greatest number of HIV infections in 47 
sub-Saharan Africa occur in women in the general population. As countries consider wider PrEP 48 
scale-up, there is need to weigh the population-level impact, cost and relative cost-effectiveness to 49 
inform priority-setting.  50 
Methods: We developed mathematical models of HIV risk to women and derived tools to highlight 51 
key considerations for PrEP programming. The models were fitted to South Africa, Zimbabwe and 52 
Kenya, spanning a range of HIV burden in sub-Saharan Africa. The impact, cost and cost-53 
effectiveness of PrEP scale-up for adolescent girls and young women (AGYW), women 25-34 years 54 
and women 35-49 years were assessed, accounting for differences in population sizes and the low 55 
program retention levels reported in demonstration projects. 56 
Results: PrEP could avert substantially more infections a year among women in general population 57 
than among FSW. The greatest number of infections could be averted annually among AGYW in 58 
South Africa (24-fold that for FSW). In Zimbabwe, the greatest number of infections could be averted 59 
among women 25-34 years (8-fold that for FSW), and in Kenya similarly between AGYW and women 60 
25-34 years (3-fold that for FSW). However, the unit costs of PrEP delivery for AGYW, women 25-34 61 
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years and women 35-49 years would have to reduce considerably (by 70.8-91.0% across scenarios) 62 
for scale-up to these populations to be as cost-effective as for FSW. 63 
Conclusions: PrEP has the potential to substantially reduce new HIV infections in HIV-endemic 64 
countries in sub-Saharan Africa. This will necessitate PrEP being made widely available beyond those 65 
at highest individual risk, and continued integration into a range of national services and at 66 
community level to significantly bring down the costs and improve cost-effectiveness. 67 
 68 
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Women remain the most affected by the global HIV epidemic. In sub-Saharan Africa, the region with 72 
the greatest HIV burden, 59% of new adult infections are among women1. In 2018, a quarter of all 73 
new infections were among adolescent girls and young women (AGYW) aged 15-24 years2, whilst 74 
female sex workers (FSW) are up to 20 times more likely to be HIV positive than women in the 75 
general population3. 76 
 77 
Oral pre-exposure prophylaxis (PrEP) has shown HIV prevention efficacy in randomised controlled 78 
trials (up to 99% risk reduction, depending on drug adherence and study population)4,5. It is hoped 79 
PrEP will address some of the drivers of HIV in women, which include lack of agency to negotiate sex 80 
and condom use1. Aside from women in sero-discordant relationships6, PrEP demonstration projects 81 
have faced challenges in retaining women7–9, raising concerns about the ability of programs to avert 82 
infections when scaled-up1. A recently completed PrEP demonstration project among FSW in South 83 
Africa reported 22% 12-month program retention rates7. Early results from programming in 84 
Kenya9,10,11 and Zimbabwe12 show even lower retention rates in AGYW than FSW.  85 
 86 
As PrEP is rolled out in countries in sub-Saharan Africa in line with 2016 normative guidance, its use 87 
has been prioritised for populations at substantial risk of HIV13, including FSW, AGYW and individuals 88 
with history of low condom use, STIs, multiple concurrent partnerships and transactional sex14–23. 89 
PrEP programs are being hosted by services tailored for groups at highest risk of infection, or in 90 
general services with screening tools used to identify those most at risk. There have been challenges 91 
with the sensitivity and specificity of screening tools, which may serve better as an initiator of client-92 
provider dialogue rather than as a determinator of eligibility13,24–27. Increasingly, there is pressure for 93 
countries to move towards universal access to PrEP as part of a rights-based approach to health28. 94 
The rights-based language of PrEP programming is shifting to refer to populations who could benefit 95 




Whilst FSW are typically women at highest HIV risk2, HIV incidence among women in the general 98 
population varies significantly by age range across countries in sub-Saharan Africa2, To date, six of 99 
the eight finalised population-based HIV impact assessments (PHIA) undertaken in sub-Saharan 100 
African countries reveal higher levels of incidence in women 25-34 years or 35-49 years than in 101 
AGYW 15-24 years29–36. Policy makers are having to weigh the potential benefits and challenges of 102 
scaling up PrEP for groups of women at lower individual levels of risk, but in whom the total number 103 
of new infections is greater due to differences in population sizes1.  104 
 105 
Decisions around PrEP scale-up are taking place in a context of limited external resources for HIV, 106 
constraints in domestic budgets and a global push for countries to prioritize resources to reach the 107 
90-90-90 treatment targets1. These decisions mirror those previously faced by policy makers in 108 
determining whether to scale up antiretroviral treatment (ART) for individuals at higher CD4 counts, 109 
balancing comparatively lower benefits for individuals with potential for greater population-level 110 
prevention effects13.  111 
 112 
Several modelling studies have evaluated the cost-effectiveness and impact of PrEP for high-risk 113 
populations in sub-Saharan Africa37–41; between key populations and men/ women in the general 114 
population42,43; between groups in the general population44–47; relative to other HIV prevention 115 
interventions and ART40,44,45,48–51. Studies typically find PrEP to be less cost-effective than other 116 
established prevention interventions or scaling up ART, but cost-effective as part of a combination 117 
prevention approach for those at greatest risk. To date no study has assessed the scale-up of PrEP 118 
from highest-risk populations (e.g. FSW) to groups of women across the general population at 119 
comparatively lower risk, weighing cost-effectiveness on an individual basis with the need to avert 120 




Our study aims to build simple mathematical models to highlight key considerations to feed into 123 
policy making, as countries consider scaling-up PrEP across a more broadly defined group of women 124 
at risk in sub-Saharan Africa. It aims to present decision makers with a range of important 125 
considerations, including PrEP cost-effectiveness, cost and estimated number of HIV infections 126 
averted on PrEP for different groups of women at population-level. We use case studies of three 127 
HIV-endemic countries: South Africa, Zimbabwe and Kenya. These countries, spanning a range of HIV 128 
burden levels in the region, have each adopted a national PrEP strategies19–21, and been at the 129 
forefront of PrEP roll-out in sub-Saharan Africa28. This study makes a first attempt to address a gap in 130 
the literature, given the limited use of real-world PrEP retention and use-effectiveness data in 131 
parameterizing modelling studies52.  132 
  133 
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Materials and Methods 134 
As the contexts in which the models are being applied are stable generalised high prevalence HIV 135 
epidemics1, we adopted static mathematical models of HIV risk53–55. Static models are a 136 
comparatively easier tool for use and communication with policy makers, and have been shown to 137 
be robust to inform policy making around the introduction of new HIV interventions over short-138 
medium time horizons in stabilised epidemics56. 139 
 140 
The mathematical models take the Bernoulli formulation of HIV risk56. In this model formulation, 141 
women’s sexual partners are assumed to come from one or more population groups, each with a 142 
given level of HIV prevalence. Women are assumed to have a certain number of partners from each 143 
of these population groups per year, with whom they have an average number of sex acts each per 144 
year. Sex acts are assumed to be peno-vaginal, which is the predominant pathway of HIV 145 
transmission to heterosexual women in sub-Saharan Africa1. Condoms are assumed to be used with 146 
partners from each population group with a given level of consistency (% of time that they are used). 147 
The risk-reduction efficacy of condoms is taken to be 85% (range 80-90%)57,58. We used estimates for 148 
women from the Partners Demonstration Project59 to relate levels of PrEP adherence to levels of HIV 149 
risk reduction. We used the 12-month PrEP programme retention levels reported in the South 150 
African TAPS demonstration project in FSW7 (the only study to date from which there is empirical 151 
evidence of 12-month PrEP retention levels in women in sub-Saharan Africa). The models also 152 
account for STI levels, levels of viral load suppression due to ART in HIV positive partners, and male 153 
circumcision. Analyses were conducted over a one-year timeframe, as PrEP is intended to cover 154 
‘seasons’ of HIV risk, and few PrEP demonstration programs have achieved significant retention in 155 
women in this context beyond the first 12 months7,9. The mathematical models, basic rules derived 156 
from them, and data used to parameterise and calibrate the models are given in the Supplementary 157 




Tools to help guide PrEP programme decision making 160 
Heatmaps were developed to help guide programme decision making using a basic set of 161 
information typically available to PrEP programmes60. They are intended to apply to women from 162 
any age group, to help programmers understand their underlying HIV risk and evaluate whether 163 
PrEP may be of benefit to them. The first set of heatmaps helps decision makers estimate the annual 164 
HIV incidence in women by number of monthly sex acts, average condom use and underlying 165 
epidemic setting (i.e. HIV prevalence in the partner population). The number of monthly sex acts, 166 
average condom use and HIV prevalence in the partner population are simulated over a range of 167 
possible levels in the sub-Saharan African context – spanning women who have very low to very high 168 
risk behaviours.  169 
 170 
The second set of heatmaps helps decision makers estimate the relative unit cost at which it will be 171 
cost-effective to scale up PrEP from a comparatively higher- (e.g. FSW) to comparatively lower-risk 172 
woman (e.g. AGYW). The cost-effectiveness ratio is defined as the incremental cost of PrEP per 173 
infection averted, per year. It accounts for the level of PrEP program retention and average PrEP 174 
adherence. The cost-effectiveness ratio and further details are given in Supplementary Materials: 175 
Supplementary Methods section 2.2 and equation S2.5. In the absence of willingness-to-pay 176 
thresholds, relative cost-effectiveness was assessed by comparing estimates of cost per infection 177 
averted between populations. It was assumed that the higher-risk group had 22% PrEP program 178 
retention levels and all women retained had PrEP adherence levels of 70-85% (corresponding to risk-179 
reduction of 73-99%59), consistent with the South African TAPS demonstration project in FSW7. Given 180 
this paucity of empirical data, PrEP program retention for the lower-risk group was simulated 181 
between ±25% of the 22% retention levels of the higher-risk group (i.e. 16.5%-27.5%), consistent 182 
with the difference between 6-month AGYW and FSW retention in Kenya9 for the lower bound, and 183 
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for the upper bound to account for data uncertainty. For lower-risk women retained in the PrEP 184 
program, it was assumed that PrEP adherence was the same as the higher-risk group.  185 
 186 
 187 
Country case studies  188 
In order to highlight key considerations to feed into decision making as countries consider scaling-up 189 
PrEP beyond those at highest-individual risk, we assessed the cost-effectiveness, cost and impact of 190 
scaling-up PrEP for women across a spectrum of high HIV risk in South Africa, Zimbabwe and Kenya. 191 
Given their significantly higher individual HIV risk1, FSW were taken as the benchmark for 192 
assessment. In comparison, we considered the scale-up of PrEP to three groups of women at high 193 
HIV risk in the general population61–63: AGYW, women 25-34 years and women 35-49 years. No 194 
further targeting of PrEP was assumed. Women aged 50+ were not evaluated given paucity of 195 
information available to parameterise and fit the models in all three country contexts29,64–67.  196 
 197 
FSW were assumed to have partners drawn from two populations: regular partners and clients. 198 
AGYW were assumed to have partners drawn from their own age group (15-24 years) and the 25-34 199 
years age group, given that 17% and 14% women 15-19 years report relationships with men at least 200 
10 years older in Zimbabwe65 and Kenya66 respectively, and 36% South African women 15-19 years 201 
report relationships with men at least 5 years older61. Women 25-34 years and women 35-49 years 202 
were assumed to have partners drawn from their own age groups given lack of data to suggest 203 
otherwise. This assumption was explored further through structural sensitivity analysis (see below 204 
section). Data to parameterise the models were drawn from the literature and fitted to the latest 205 
national estimates of HIV incidence29,68–75 using Bayesian Monte Carlo Filtering with Latin Hypercube 206 





FSW were assumed to have 12-month PrEP program retention and adherence levels consistent with 210 
the TAPS demonstration project7. All other women were assumed to have program retention levels 211 
between ±25% of these 12-month FSW retention levels9, and the same adherence levels as FSW 212 
retained in the program. To explore the role of adherence, the parametric uncertainty analyses were 213 
repeated with 1) 25% lower HIV risk-reduction across all groups, and 2) 25% lower HIV risk-reduction 214 
across AGYW, women 25-34 years and women 35-49 years (unchanged among FSW). 215 
  216 
As a comparison, we estimated the current unit costs of PrEP program delivery per person retained 217 
after 12-months (Table 1). We assumed FSW were offered PrEP through programmes with outreach 218 
and community mobilisation components and all other women were offered PrEP through sexual 219 
and reproductive health services, with AGYW having larger counselling components. Further 220 
information on the methodology and assumptions are set out in Supplementary Materials: 221 
Supplementary Methods section 2.2 and in the assumptions column in Table 1. 222 
 223 
 224 
  225 
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Structural sensitivity analysis 226 
We explored how the model outcomes change if women aged 25-34 years have an additional 227 
partner group from an older male population (35-49 years); illustratively assuming 50% the number 228 
of partners a year from this age group as had by women 35-49 years. 229 
 230 
Further details on the methods are set out in Supplementary Materials: Supplementary Methods, 231 
and all data used in the study in Supplementary Materials: Table S2. 232 




Figure 1 shows the estimated annual HIV incidence in women, according to their number of monthly 235 
sex acts and their average condom use. The estimates are shown for four cases: underlying HIV 236 
prevalence in partner population of 5%, 10%, 20% and 40%.  237 
 238 
Figure 1 shows that where women’s partners come from a population with HIV prevalence of up to 239 
5%, women will be below the 3%13 WHO-recommended annual HIV incidence threshold for PrEP 240 
where the number of sex acts a month is up to 10 and average condom use is at least 50% (areas 241 
shaded yellow). As the underlying HIV prevalence in the partner population increases, women will 242 
need higher levels of condom consistency or to engage in fewer sex acts a month to be below the 243 
WHO incidence threshold for PrEP (areas shaded orange-red). Where women’s partner population 244 
have a prevalence of 40%, women will almost uniformly be above the threshold for PrEP.  245 
 246 
The relative cost at which PrEP will be equally as cost-effective to be scaled-up in the lower-risk 247 
group as it will be in the higher-risk group, is demonstrated in Figure 2 for four scenarios: underlying 248 
HIV prevalence in the lower-risk women’s partner population of 10%, 20%, 30% and 40%, with HIV 249 
prevalence in the higher-risk women partner population of 40%. The equivalent figure 250 
corresponding to 20% HIV prevalence in the higher-risk women’s partner population is given in 251 
Supplementary Materials: Figure S4. The relative cost at which PrEP will be equally as cost-effective 252 
is shown by the relative average condom use in the lower-risk group compared to the higher-risk 253 
group (x-axis), and the relative number of sex acts a month for women in the lower-risk group 254 
compared to the higher-risk group (y-axis).  255 
 256 
Where HIV prevalence in the lower-risk women’s partner population is 10%, the results show that 257 
the unit cost of PrEP in the lower-risk group will have to be much lower than in the higher-risk group 258 
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for PrEP roll-out to be equally as cost-effective (areas shaded yellow), other than where the numbers 259 
of monthly sex acts in the lower-risk group exceeds that of the higher-risk group (areas shaded 260 
green). This is independent of the levels of condom use by either the higher- or lower-risk women. 261 
As HIV prevalence increases in the lower-risk women’s partner population relative to the higher-risk 262 
women’s partner population, PrEP will be equally cost-effective between the two groups at 263 
increasingly higher unit costs for the lower-risk group relative to the higher-risk group. Relative cost-264 
effectiveness does not, however, imply affordability at either individual or population level40. 265 
 266 
In Figure 2, 100% on the axes represents the point at which condom use or the number of sex acts 267 
per month in the “lower-risk” woman goes from being lower than to the same as in the “higher-risk 268 
woman”. This may represent the case that, for example, an AGYW engaging in transactional sex has 269 
higher risk behaviours (e.g. lower condom use) than a FSW (e.g. with relatively high levels of condom 270 
use).  271 
 272 
Country case studies  273 
The model fits to HIV incidence for South Africa, Zimbabwe and Kenya are given in Supplementary 274 
Materials: Figures S1-S3.  275 
Figure 3 shows the maximum unit cost of PrEP for AGYW, women 25-34 years and women 35-49 276 
years, relative to the unit cost of PrEP for FSW, for scale-up to be equally as cost-effective as it is in 277 
FSW. This is shown for South Africa (blue), Zimbabwe (orange) and Kenya (green). As comparators, 278 
the estimated current relative unit costs are shown (cream). The underlying data for Figure 3 are 279 
given in Table 2. 280 
 281 
For example, in the case of AGYW in South Africa, Figure 3 shows that PrEP will be equally cost-282 
effective for AGYW as for FSW at a maximum median relative unit cost of 23.3 % (95% CrI: 13.3%, 283 
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36.8%) (furthest left blue boxplot). The current estimated unit cost of PrEP in AGYW relative to FSW 284 
in South Africa is median 79.8 % (95% CrI: 73.0%, 87.0 %) (furthest left cream boxplot). If the cost of 285 
PrEP for AGYW in South Africa dropped by median 70.8% (95% CrI: 53.2%, 83.4 %) it would be 286 
equally as cost-effective as for FSW.  287 
Otherwise, across all other scenarios in all three countries, the current unit cost of PrEP for AGYW, 288 
women 25-34 years and women 35-49 years would have to drop between median 71.8-91.0% (95% 289 
CrIs spanning: 50.8%, 96.5%) to be equally as cost-effective.  290 
 291 
Figure 4 illustrates the estimated number of infections that could be averted a year due to PrEP in 292 
each high-risk women population group, in each country, for every $100,000 available for PrEP 293 
programming.  294 
 295 
Given the differences in relative population sizes, Figure 5 demonstrates the relative number of 296 
infections that could be averted a year with PrEP at equal coverage levels in AGYW, women 25-34 297 
years and women 35-49 years as in FSW. In comparison to the number of infections averted annually 298 
in FSW in South Africa, a median 24 times (95% CrI:12, 45) the number of HIV infections could be 299 
averted in AGYW, median 14 times (95% CrI:7, 27) in women 25-34 years, and median 8 times (95% 300 
CrI:4, 17) in women 35-49 years, if PrEP were rolled out at the same coverage levels across 301 
populations. However, the cost of these programmes relative to the cost of programmes for FSW 302 
would be a median 28.3-, 26.7- and 18.7-fold higher for AGYW, for women 25-34 years and for women 303 
35-49 years, respectively (Supplementary Materials: Table 4a). 304 
In Zimbabwe, a median 4 times (95% CrI:2, 9) the number of annual HIV infections could be averted 305 
in AGYW, median 8 times (95% CrI:3, 14) in women 25-34 years, and median 3 times (95% CrI:2, 5) in 306 
women 35-49 years, in comparison to FSW with equal PrEP program coverage. However, the cost of 307 
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these programmes relative to the cost of programmes for FSW would be a median 21.9-, 15.2- and 308 
7.0-fold higher for AGYW, for women 25-34 years and for women 35-49 years, respectively. 309 
In Kenya, a median 3 times (95% CrI:2, 8) the number of HIV infections could be averted in AGYW, 310 
median 3 times (95% CrI:1, 5) in women 25-34 years, and median 1 times (95% CrI:1, 3) in women 35-311 
49 years, in comparison to FSW with equal PrEP program coverage. However, the cost of these 312 
programmes relative to the cost of programmes for FSW would be a median 27.4-, 16.4- and 8.5-fold 313 
higher for AGYW, for women 25-34 years and for women 35-49 years, respectively. 314 
 315 
 316 
Sensitivity analyses 317 
Repeating the analyses shown in Figures 3 and 5 with 25% reduced adherence-related HIV risk-318 
reduction across all female groups led to <0.01% change across the scenarios (Supplementary 319 
Materials: Tables S9 and S10). Repeating these analyses with 25% reduced adherence-related HIV risk 320 
reduction among all non-FSW women groups led to <0.3% change across the scenarios 321 
(Supplementary Materials: Tables S11 and S12). Repeating these analyses under the structural 322 
sensitivity analysis led to <1% change across scenarios (Supplementary Materials: Tables S13 and S14). 323 




This is the first study to assess the potential impact and relative cost-effectiveness of PrEP scale-up 326 
from FSW to groups of women in the general population groups among countries in sub-Saharan 327 
Africa, using updated data from PrEP programming to highlight key considerations for decision 328 
making. Our findings  may be of interest to national policy makers as they consider adopting PrEP 329 
policies based on more inclusive definitions of people at risk in line with conclusions from other 330 
studies that PrEP will only have substantial effect on generalised epidemics if scaled-up beyond 331 
highest-risk groups40,45,46. PrEP should be offered to women at highest HIV risk, such FSW, for whom 332 
it is most cost-effective. However, only by extending PrEP to women at comparatively lower risk will 333 
new HIV infections reduce substantially.  334 
We developed tools to guide PrEP programming: heatmaps to estimate the annual HIV incidence in 335 
women (Figure 1) and relative cost-effectiveness between higher- and lower-risk women (Figure 2). 336 
By adapting the models to three countries spanning the spectrum of high HIV burden contexts in 337 
sub-Saharan Africa, we have shown that the unit costs of PrEP delivery for AGYW, women 25-34 338 
years and women 35-49 years would have to reduce considerably (by median 70.8-91.0%  across 339 
scenarios) for scale-up to these populations to be as cost-effective as for FSW.  340 
Rolling out PrEP for women in the general population has potential to substantially impact on the 341 
countries’ HIV epidemics. In South Africa, PrEP has the potential to avert approximately 24 times the 342 
number of infections annually in AGYW as in FSW when scaled up at equal coverage levels, and 343 
approximately 14 and 8 times the number in women 25-34 and 35-49 years respectively. In 344 
Zimbabwe approximately 8 times the number of infections could be averted annually in women 25-345 
34 years as in FSW, and approximately 4 and 3 times the number in AGYW and women 35-49 years 346 
respectively. In Kenya, approximately 3 times the number of infections could be averted annually in 347 
AGYW and in women 25-34 years as in FSW, and around the same number in women 35-49 years as 348 
in FSW.  349 
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However, scaling up PrEP programs among the general population is likely to be costly and pose 350 
challenges of affordability. This study has shown that scaling up PrEP programs for AGYW, women 351 
25-34 years and women 35-49 years would cost a median 18.7-28.3 times (across scenarios) the cost 352 
of programmes with equal coverage levels among FSW in South Africa. In Zimbabwe, programmes 353 
for these groups of women with equal coverage would cost a median 7.0-21.9 times the cost of 354 
programmes for FSW, and in Kenya, a median 8.5-27.4 times the cost of programmes for FSW. 355 
Policy makers will need to weigh these prospects for population-level impact against affordability, in 356 
view of current program costs, budget constraints and program sustainability (although PrEP is for 357 
seasons of risk, rather than long-term use, so may be more feasibly scaled back as population 358 
incidence decreases). Relative cost-effectiveness does not indicate affordability at individual or 359 
population level40. Scaling up PrEP for women in the general population has the potential to drive 360 
cost reductions through economies of scale. This will require countries to continue to integrate PrEP 361 
into a range of health, non-health and community services for women in the general population19–21, 362 
which in some instances (e.g. education) may be challenging in local cultural contexts. Future long-363 
acting PrEP formulations under investigation76–78, may also help improve cost-effectiveness, if they 364 
increase HIV prevention use-effectiveness through improved product adherence and retention. This 365 
study complements the ongoing effort to use mathematical models as tools to understand PrEP 366 
scale-up in other countries outside of South Africa37–43,44–51,79,80. 367 
 368 
Limitations 369 
This study was conducted using static mathematical models, given their comparative ease for use in 370 
policy making and they require a narrower and more readily available set of data in comparison to 371 
the more complex dynamic models typically used to HIV decision making. However, these models do 372 
not assess long-term cost-effectiveness81 or capture downstream infections averted in partner 373 
populations. Studies have shown that introducing HIV prevention interventions to high-risk groups 374 
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has greatest impact on reducing onwards transmission early in epidemics when prevalence is low 375 
and the basic reproductive rate is high, than in endemic high-burden contexts82,83, such as those in 376 
which our model is applied1. Therefore, if the study were extended to look at the impact of PrEP 377 
beyond its recipients, the estimated number of infections averted would likely increase, the costs 378 
per infection averted would likely decrease, and modest changes would be expected comparing the 379 
relative impact between high-risk populations.  380 
 381 
The heatmap tools in Figures 1 and 2 were developed to help PrEP programmers estimate women’s 382 
HIV risk using a basic set of information typically available to PrEP programmes (number of sex acts/ 383 
month, condom use, estimated HIV prevalence in partner population)60. They do not account for 384 
more granular information, such as the presence of STIs in sexual partnerships, ART use or viral 385 
suppression among HIV positive partners, and male circumcision levels. Such information is needed 386 
to estimate a woman’s HIV risk more accurately. As such, the heatmap tools should be taken to be 387 
indicative, rather than precise, tools for estimating a woman’s HIV risk. 388 
 389 
Much of the data used to characterise women are limited by age and lack of reliable data on 390 
numbers of partners and sex acts. Sexual behaviour data is subject to under-reporting, and when 391 
collected through demographic health surveys, reporting as percentages makes it difficult to derive 392 
meaningful limits or statistic distributions for the underlying data. Cost estimates are limited by 393 
assumptions on how subgroups are reached and scarcity of empirical data. Data uncertainty is 394 
addressed to some extent through the uncertainty analysis. 395 
 396 
This study was parameterised using population averages for broadly defined groups. It does not 397 
account for significant behavioural heterogeneity that exists within each of these groups nor in 398 
differences in HIV burden at local-levels, potentially masking important risk groups and population 399 
interactions. Accordingly, reported population mixing between women 15-19 years and men 5-10 400 
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years older in these countries was represented by AGYW (15-24 years) drawing partners from male 401 
populations 15-24 years and 25-34 years. Lack of available data to parameterize women 50 years+ 402 
meant it was not possible to explore the scale-up of PrEP to this population group.  403 
 404 
This assessment is limited by a paucity of empirical 12-month PrEP programme retention data for 405 
women in sub-Saharan Africa7,11. Potential differences in PrEP programme retention by female 406 
population group were accounted for to some extent in the sensitivity analyses. Should future PrEP 407 
programmes be able to retain women for longer than 12-months, it is possible that greater 408 
programme efforts will be needed to maintain programme retention and drug adherence (e.g. 409 
retention support, client follow up), which may reduce the cost-effectiveness of programmes over 410 
longer time horizons. This study also does not explicitly account for other PrEP program cascade 411 
factors, such as uptake. Doing so would affect the relative estimates of PrEP effectiveness where at 412 
least one female population has materially different program uptake than the others.  413 
 414 
 415 
Conclusion  416 
PrEP has the potential to significantly reduce the numbers of new HIV infections in HIV-endemic 417 
countries in sub-Saharan Africa, even considering low levels of PrEP program retention in women. 418 
This will necessitate PrEP being made widely available beyond those at highest individual risk, 419 
including to women in the general population. Wide-scale roll out will require integration of PrEP 420 
into a wide range of national services and at community level, in order to significantly bring down 421 




Country Population  
Current 
unit cost  




Drugs only  
(min - max) Specific Assumptions 
South Africa FSW 190 – 210 130 57 - 80 Unit costs measured during a demonstration project in Johannesburg and 
Pretoria via FSW clinics. Costs reported by Eakle et al7 included direct costs 
(eg, antiretrovirals, laboratory tests and consumables, labour and equipment) 
and indirect costs (eg, management, utilities, and transportation). We 
allocated outreach, demand creation and HCT costs to a unit cost of per 
person-year on PrEP as these were reported separately. 
South Africa AGYW (15-24 
years) 
149 – 169 89 57 - 80 Unit costs estimated from local data and with input from several 
demonstration projects in South Africa. Costs reported by Meyer-Rath et al84 
included direct costs (eg, antiretrovirals, laboratory tests and consumables, 
labour and equipment), indirect costs (eg, management, utilities, and 
transportation), and outreach, demand creation and HCT costs. These 
estimates reflect the authors’ estimation of costs among female adolescents. 
South Africa Women (25-34 
years) 
128 – 148 68 57 - 80 Unit costs estimated from local data and with input from several 
demonstration projects in South Africa. Costs reported by Meyer-Rath et al84 
included direct costs (eg, antiretrovirals, laboratory tests and consumables, 
labour and equipment), indirect costs (eg, management, utilities, and 
transportation), and outreach, demand creation and HCT costs. These 
estimates reflect the authors’ estimation of costs among young women. 
South Africa Women (35-49 
years) 
87 – 107 27 57 - 80 Unit costs estimated from local data and with input from several 
demonstration projects in South Africa. Costs reported by Meyer-Rath et al84 
included direct costs (eg, antiretrovirals, laboratory tests and consumables, 
labour and equipment), indirect costs (eg, management, utilities, and 
transportation), and outreach, demand creation and HCT costs. These 
estimates reflect the authors estimation of costs among pregnant women - 
we assumed for this lowest risk population, the cost will be similar to those 
attending ANC. 
Zimbabwe FSW 293 – 317 237 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.85 
Zimbabwe AGYW (15-24 
years) 
219 – 243 163 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.85 
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Zimbabwe Women (25-34 
years) 
181 - 204 124 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.85 
Zimbabwe Women (35-49 
years) 
106 - 130 50 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.85 
      
Kenya FSW 399 - 423 343 57 - 80 Unit costs measured in preparation for a demonstration project in Nairobi via 
SWOP clinics (for FSW). Costs reported by Cremin et al86 included direct costs 
(eg, antiretrovirals, laboratory tests and consumables, labour and equipment), 
related costs (eg, outreach and demand creation), and indirect costs (eg, 
management, utilities, and transportation).  
Kenya AGYW (15-24 
years) 
358 - 382 302 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al87 included fixed (start-up 
costs, such as microplanning and training, capital, overheads (e.g. building 
costs, transportation, and airtime) and administrative and supervisory 
personnel) or variable (drugs, clinical personnel direct service costs, 
laboratory testing, and other supplies). These estimates reflect the authors 
measurement of costs among the highest risk subpopulation in the general 
population. 
Kenya Women (25-34 
years) 
294 - 318 238 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al87 included fixed (start-up 
costs, such as microplanning and training, capital, overheads (e.g. building 
costs, transportation, and airtime) and administrative and supervisory 
personnel) or variable (drugs, clinical personnel direct service costs, 
laboratory testing, and other supplies). These estimates reflect the authors 
measurement of costs among all women. 
Kenya Women (35-49 
years) 
185 - 209 129 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al87 included fixed (start-up 
costs, such as microplanning and training, capital, overheads (e.g. building 
costs, transportation, and airtime) and administrative and supervisory 
personnel) or variable (drugs, clinical personnel direct service costs, 
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laboratory testing, and other supplies). These estimates reflect the authors 
measurement of costs among all women excluding screening costs. 
 424 
Table 1: Current unit cost estimates per person retained on PrEP after 12-months by population and country.  425 
The estimated current unit costs for FSW, AGYW, women 25-34 years and women 35-49 years are shown disaggregated by the portion that is service delivery costs and the portion that is drug 426 
costs. The costs were calculated in line with the methodology set out in Supplementary Materials: Methods section 2.2. Service delivery costs were taken from demonstration projects and 427 
previous costing publications in Kenya86,87 and South Africa7. For Zimbabwe, non-tradable components of the South African estimates were transferred using purchasing power parities88. Costs 428 
in USD 2017. Ranges were only available for drug unit costs. The far right hand side column of the table sets out specific assumptions made in the calculations.  429 
*For these calculations, we replaced reported drug costs by a range of USD57-80. The low bound is the internationally traded value of USD3.75 430 
(https://www.theglobalfund.org/media/5813/ppm_arvreferencepricing_table_en.pdf) plus 25% top up of freight and distribution costs in country (15% shipping and handling charges, and 431 
10% for drug distribution costs). The high bound is the highest reported price for drugs in the demonstration projects - 30 days TDF/FTC at USD6.75. 432 
**transferability of costs between countries followed standard guidelines (https://pdfs.semanticscholar.org/36ab/74fd24fb883db703c475364c34ad574a3f35.pdf) 433 
*** Purchasing Power Parities (PPP) 434 
 435 




Figure 1: Women’s estimated HIV incidence by risk factor.  438 
The heatmaps show the estimated annual HIV incidence in women according to their number of sex acts per month 439 
(number of partners multiplied by average number of sex acts with each per month), and average condom use. The 440 
estimated annual HIV incidence is shown by colour (according to the colour key on the right-hand side of the graph) in 441 
incidence increments of 1% or 1 per 100 person years. An annual incidence of at least 3% or 3 per 100 person years is 442 
coloured light orange and corresponds to the WHO recommended threshold for PrEP eligibility13. The 4 heatmaps 443 
correspond respectively (left to right, top to bottom) to underlying partner HIV prevalence of 5%, 10%, 20% and 40%. The 444 
heatmaps are calculated using equation (S1.1) from the Supplementary Materials: Supplementary Methods, section Model 445 
Structure, assuming that a women’s partners are drawn from a single population and no women are on PrEP. 446 




Figure 2: Relative unit cost at which it is cost-effective to scale up PrEP from a higher- to lower-risk women group.  449 
The heatmaps show the relative unit cost at which it is cost-effective to scale up PrEP from a higher- to a lower-risk group. 450 
The relative unit cost at which PrEP is cost-effective is shown by the relative average condom use in the lower-risk group 451 
compared to the higher-risk group (x-axis), and the relative number of sex acts a month for women in the lower-risk group 452 
compared to the higher-risk group (y-axis). 100% on the axes represents the point at which the condom use or number of 453 
sex acts in the lower-risk group goes from being lower than to higher than in the levels in the higher-risk group. 454 
The unit cost of PrEP in the lower-risk group relative to the higher-risk group at which PrEP is equally cost-effective between 455 
the two groups is shown by colour, according to the colour key on the right-hand side of the graph. A colour within the 456 
yellow spectrum denotes that the relative unit cost of PrEP in the lower-risk group relative to the higher-risk group has to be 457 
less than 1 for it to be equally as cost cost-effective. A colour within the green spectrum denotes that the relative unit cost 458 
of PrEP in the lower-risk group relative to the higher-risk group will be greater than 1 for it to be equally as cost cost-459 
effective. The 4 heatmaps correspond respectively (left to right, top to bottom) to underlying partner HIV prevalence of 460 
10%, 20%, 30% and 40% in the lower-risk group’s partner population and all of them corresponding to 40% HIV prevalence 461 
in the higher-risk women’s partner population. The heatmaps are calculated using equation (S1.5) from the Supplementary 462 
Materials: Supplementary Methods, section Model Structure, assuming that women’s partners are drawn from a single 463 
population each. The higher-risk group are assumed to have 12-month PrEP program retention levels of 22%7 and 464 
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adherence levels of 70-85% (corresponding to a risk reduction of 73-99%59). The PrEP program retention levels for the 465 
lower-risk group were simulated between +/- 25% the retention of the higher-risk group9. For those lower-risk women 466 
retained in the PrEP program, it was assumed that PrEP adherence was the same as the higher-risk group. The axes were 467 
capped at 140% relative condom use or number of sex acts/ month, in order to depict the most pertinent trends for 468 
programmers in the heatmaps. 469 




Figure 3: Relative unit cost of PrEP for scale-up to be equally as cost-effective as for FSW.  472 
The boxplot shows the maximum unit cost of PrEP per year for AGYW, women 25-34 years or women 35-49 years relative to 473 
the unit cost of PrEP for FSW, for PrEP scale-up in these populations to be equally as cost-effective as it is for FSW (bright-474 
coloured boxes). The maximum relative unit costs are shown, grouped left to right, for AGYW, women 25-34 years or 475 
women 35-49 years. Within each age grouping, the results are show by country, left to right, for South Africa (in blue), 476 
Zimbabwe (in orange) and Kenya (in green). The maximum relative unit costs are calculated using equation (S2.5) from 477 
Supplementary Materials: Supplementary Methods, section Model Structure and assume that 12-month PrEP program 478 
retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for FSW, taken to be 479 
22%, in line with the results of the TAPS demonstration project7. As comparisons, current estimates of the unit costs of PrEP 480 
for AGYW, women 25-34 years and women 35-49 years, relative to the unit cost of PrEP for FSW are shown for all countries 481 
(in cream), calculated using data from Table 1. The abbreviations used in the graph are as follows: AGYW denotes 482 




    Women Population Group 
Country Unit Cost Relative to FSWs AGYW (15-24 years) Women 25-34 years Women 35-49 years 
South 
Africa 
Maximum Relative Unit Cost to be as Cost-
Effective as for FSW 23.3 % ( 13.3 % , 36.8 % ) 16.2 % ( 9.1 % , 26.0 % ) 10.5 % ( 5.7 % , 18.0 % ) 
Estimated Current Unit Cost Relative to FSW 79.6 % ( 72.4 % , 86.7 % ) 68.7 % ( 62.7 % , 75.8 % ) 48.3 % ( 42.4 % , 54.7 % ) 
% Reduction in Current Unit Cost Needed to be 
Equally as Cost-Effective as for FSW -70.8 % ( -83.4 % , -53.2 % ) -76.2 % ( -87.0 % , -62.6 % ) -78.4 % ( -88.1 % , -61.8 % ) 
Zimbabwe 
Maximum Relative Unit Cost to be as Cost-
Effective as for FSW 7.1 % ( 2.7 % , 14.9 % ) 17.7 % ( 7.1 % , 31.2 % ) 11.0 % ( 5.5 % , 17.2 % ) 
Estimated Current Unit Cost Relative to FSW 75.6 % ( 70.8 % , 80.8 % ) 63.0 % ( 58 % , 67.7 % ) 38.8 % ( 34.1 % , 42.7 % ) 
% Reduction in Current Unit Cost Needed to be 
Equally as Cost-Effective as for FSW -90.4 % ( -96.5 % , -80.6 % ) -71.8 % ( -88.9 % , -50.8 % ) -72.0 % ( -86.1 % , -53.6 % ) 
Kenya 
Maximum Relative Unit Cost to be as Cost-
Effective as for FSW 8.1 % ( 3.9 % , 18.5 % ) 9.1 % ( 3.6 % , 17.7 % ) 6.4 % ( 3.1 % , 11.6 % ) 
Estimated Current Unit Cost Relative to FSW 90.3 % ( 86.2 % , 94.8 % ) 74.9 % ( 71.1 % , 78.4 % ) 48.1 % ( 45.1 % , 51.6 % ) 
% Reduction in Current Unit Cost Needed to be 
Equally as Cost-Effective as for FSW -91 % ( -95.7 % , -79.6 % ) -88 % ( -95.3 % , -76.6 % ) -86.7 % ( -93.7 % , -75.4 % ) 
Table 2: Maximum Unit Costs of PrEP for AGYW, Women 25-34 years and Women 35-49 years to be Equally as Cost-Effective as for FSW, with Estimates of Current Relative Unit Costs.  485 
 486 
For each country, the table displays three rows of information. The first row shows the maximum relative unit costs of PrEP in AGYW, women 25-34 years and women 35-49 years relative to 487 
the unit costs of PrEP for FSW, for PrEP to be equally as cost-effective. This is calculated using equation S1.5 in Supplementary Materials: Methods, considering the estimated relative annual 488 
HIV risk reduction on PrEP between the population groups.  489 
The second row shows the estimated current relative unit costs between the populations, calculated using the data set out in Table 1. 490 
The third row shows the % reduction in the current unit cost needed for PrEP to be equally as cost-effective for AGYW, women 25-34 years or women 35-49 years as for FSW, considering the 491 
data set out in Table 1.  492 
The comparisons are shown separately for South Africa, Zimbabwe and Kenya. The values shown in the table outside the brackets are the median values, and the values shown in the brackets 493 




Figure 4: Boxplot of the number of HIV infections that could be averted a year due to PrEP, for each $100k available for 496 
PrEP programming.  497 
The boxplot shows, for each $100k available for PrEP programming a year for FSW, AGYW, women 25-34 years and women 498 
35-49 years, the total number of infections that could be averted a year due to PrEP. The number of infections that could be 499 
averted a year for each $100k available for PrEP are shown, grouped left to right, for FSW, AGYW, women 25-34 years or 500 
women 35-49 years. Within each age grouping, the results are shown by country, left to right, for South Africa (in blue), 501 
Zimbabwe (in orange) and Kenya (in green). The number of infections averted a year is calculated using equation (S2.10) 502 
from Supplementary Materials: Supplementary Methods, section Model Structure and assumes that 12-month PrEP 503 
program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for FSW, taken 504 
to be 22%, in line with the results of the TAPS demonstration project7. The unit costs of PrEP for each high-risk women 505 
group are as stated in Table 1. These estimates hold until PrEP saturation (determined by retention levels and population 506 
size) has been reached in the smallest population group – in this case, FSW. After this point, no additional financial 507 





Figure 5: Violin plot of the relative number of infections averted a year on PrEP with equal program coverage as in FSW. 511 
The violin plot shows the relative number of infections that could be averted a year in HIV negative AGYW, women 25-34 512 
years or women 35-49 years, compared to in FSW, if PrEP were scaled up at the same coverage levels as in HIV negative 513 
FSW. The relative number of infections that could be averted are shown, grouped left to right, for South Africa (in blue), 514 
Zimbabwe (in orange) and Kenya (in green). In the violin plots, the white dots represent the median values, the thick black 515 
vertical lines represent the interquartile range, the vertical length of the violin represents the range of values and the width 516 
of the violin represents the frequency with which those values occur. The relative number of infections that could be averted 517 
are calculated using equation (S2.9) from Supplementary Materials: Supplementary Methods, section Model Structure and 518 
assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of 519 
retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration project7. If these comparisons 520 
were applied to more narrowly defined sub-population groups, the wide variability in the violin plot estimates highlight that 521 
decisions around PrEP scale-up will depend on the specific characteristics of the sub-population groups under consideration. 522 
The abbreviations used in the graph are as follows: AGYW denotes adolescent girls and young women 15-24 years, 25-34 yr 523 
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We use a static Bernoulli formulation of HIV risk1. The sexual partners of high-risk women from 
population 𝑗𝑗 are assumed to come from populations 𝑖𝑖 in which the proportion HIV infected is 𝑝𝑝𝑖𝑖. We 
assume an average probability of HIV transmission, 𝛽𝛽𝑓𝑓, per sexual contact with an HIV infected male 
partner. High risk women are assumed to have 𝐶𝐶𝑖𝑖 number of partners from each population a year, 
with whom they have an average of 𝑛𝑛𝑖𝑖 sex acts a year each. Condoms are assumed to be used with 
partners from each population with consistency 𝛾𝛾𝑖𝑖𝑖𝑖 and have an HIV risk reduction efficacy, 𝜀𝜀, 
including slippage and breakage. Upon introduction, high-risk women from population 𝑗𝑗 are assumed 
to adhere to PrEP at an average level 𝛼𝛼𝑖𝑖, which corresponds to a level of HIV risk reduction, 𝜃𝜃𝛼𝛼𝑗𝑗 . 
They are assumed to have 12-month program retention levels 𝑟𝑟𝑖𝑖. Sex acts are assumed to be peno-
vaginal, the predominant pathway of HIV transmission to heterosexual women in sub-Saharan 
Africa.2  
 
1.0 Individual level - Simple tools to help guide PrEP programme decision making 
1.1 Assessment of HIV risk by risk factor 
For the first analysis of HIV risk, we consider a simple model of HIV risk to a single high-risk woman 
with partners drawn from a single male population. HIV risk to an individual high-risk woman in the 
absence of PrEP is given by 
𝜋𝜋(0) = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓(1− 𝜀𝜀𝛾𝛾)�
𝑛𝑛




and on PrEP is 
𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) = 1 − �𝑝𝑝 � 1 − 𝛽𝛽𝑓𝑓 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾)�
𝑛𝑛




Using equations (S1.1) and (S1.2), HIV risk reduction on PrEP is given by 
𝜋𝜋(0) − 𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) 
(S1.3) 
Heatmaps to estimate HIV incidence in women 
Heatmaps were developed using equation (S1.1) to help decision makers estimate the annual HIV 
incidence in women by number of monthly sex acts, average condom use and underlying epidemic 
setting. We demonstrated four different example epidemic settings: underlying HIV prevalence in 
partner populations of 5%, 10%, 20% and 40%. In many sub-Saharan African contexts, 5% HIV 
prevalence is illustrative of HIV prevalence in males 15-24 years, 5-20% the HIV prevalence in males 
25-49 years, and 20-40% the HIV prevalence in the clients of FSW (Supporting Information: Table 
S2). 
In order to parameterise the model to the spectrum of HIV risk faced by women in sub-Saharan 
Africa, equation (S1.1) was simulated across the parameter ranges set out in Supplementary 




1.2 Simple rule to estimate relative cost-effectiveness 
In estimating the relative cost-effectiveness among women at risk, we considered two high-risk 
women of different risk. One woman is drawn from a traditionally higher-risk population (e.g. female 
sex workers (FSW)) and the other from a relatively lower-risk female population (e.g. adolescent girls 
and young women aged 15-24 years (AGYW)), denoted 𝐻𝐻and 𝐿𝐿 respectively. For simplicity, each 
high-risk woman is assumed to draw their partners from one population group.  
Cost-effectiveness is defined as the incremental cost of PrEP for a woman retained at level 𝑟𝑟𝑖𝑖 in a 
PrEP program over a 12-month period, divided by the risk reduction achieved on PrEP when adhered 
to at level 𝛼𝛼 with retention 𝑟𝑟𝑖𝑖 over the 12-month period. In the absence of willingness-to-pay 
thresholds, relative cost-effectiveness was assessed by comparing these estimates of cost per infection 
averted between populations. 
Analysis was conducted over a one-year timeframe, as PrEP is intended for seasons of risk, and few 
PrEP demonstration programs have achieved significant retention in women in this context beyond 
the first 12 months.3,4 Let 𝜋𝜋𝐻𝐻 and 𝜋𝜋𝐿𝐿 denote the respective HIV risk for each woman, with subscripts 
𝐻𝐻and 𝐿𝐿 denoting high and low risk groups Let $𝑋𝑋𝐻𝐻 and $𝑋𝑋𝐿𝐿be the 12-month unit costs of PrEP for 
each woman (the incremental cost of PrEP for a woman retained in a PrEP program over a 12-month 
period). 





















To derive a simple formulation of equation (S1.5) that is intuitive for policy makers and programmers 
in practical real-world settings, we simplify equations (S1.1) and (S1.2) using binomial theorem. 
Using the example of equation (S1.2), where 𝛽𝛽(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1− 𝜀𝜀𝛾𝛾) ≪ 1 we have: 
𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) ≈ 1 − �𝑝𝑝 � 1 − 𝑛𝑛𝛽𝛽𝑓𝑓 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾)� + (1 − 𝑝𝑝)�
𝐶𝐶
  
           ≈ 1 − �1 − 𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾)�
𝐶𝐶
  
for  𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾) ≪ 1, 
𝜋𝜋(𝜃𝜃𝛼𝛼𝑗𝑗) ≈ 𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾).  
(S1.6) 
In other words, the HIV risk reduction to an individual on PrEP can be approximated by the total 
number of sex acts per unit time multiplied by the partner HIV prevalence, the basic risk of HIV 
transmission through peno-vaginal sex (0.0006 - 0.00115), the average proportion of sex acts not 
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protected by condoms, and the use-effectiveness of PrEP. The use-effectiveness of PrEP is defined as 
the HIV-risk reduction through use of PrEP at a given level of adherence, for a population with a 
given average program retention level. 
 
Thus the risk reduction in equation (S1.3) is approximately 
𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝜀𝜀𝛾𝛾) − 𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾), and simplifies to 
𝐶𝐶𝑝𝑝𝑛𝑛𝛽𝛽(1 − 𝜀𝜀𝛾𝛾)𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗. 
(S1.7) 
Therefore, when 𝛽𝛽 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾) ≪ 1 and 𝑝𝑝𝑛𝑛𝛽𝛽 �1 − 𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗� (1 − 𝜀𝜀𝛾𝛾) ≪ 1,the condition for 









The relationship on relative cost of PrEP is summarised as follows. 
 
Simple rule to draw insights around relative cost-effectiveness of PrEP 
This rule may help policy makers draw qualitative program insights around conditions under which it 
may be equally cost-effective to roll out PrEP in a lower-risk group as in a higher-risk group. This 
rule can be approximated based on information typically estimated by PrEP programs6. The relative 
measures stated are for lower-risk women compared to higher-risk women.  
 
1.3 Relative risk reduction on PrEP 
Heatmaps to estimate the relative unit cost at which PrEP scale-up from higher- to lower-risk women 
is cost-effective 
Heatmaps were developed using equation (S1.5) to help decision makers estimate the relative unit 
cost at which it will be cost-effective to scale up PrEP from a comparatively higher- (e.g. FSW) to 
comparatively lower-risk woman (e.g. AGYW), also using the number of monthly sex acts, average 
condom use and underlying epidemic setting. Different epidemic settings were illustrated by taking 
HIV prevalence in the higher-risk women’s partner population of either 20% or 40%. For each of 
these scenarios, HIV prevalence in the lower-risk women’s partner population was then simulated at 
1/4, 1/2, 3/4 and 1 times the prevalence of the higher-risk women’s partner population (i.e. 5%, 10%, 
15% and 20%; and 10%, 20%, 30% and 40% respectively). These scenarios span a range of epidemic 
settings in sub-Saharan Africa7. 
It was assumed that the higher-risk group had 22% PrEP program retention levels and all women 
retained had PrEP adherence levels of 70-85% (corresponding to risk-reduction of 73-99%8), 
consistent with the South African TAPS demonstration project in FSW3. PrEP program retention for 
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the lower-risk group was simulated between ±25% of the 22% retention levels of the higher-risk 
group (i.e. 16.5%-27.5%), consistent with the difference between AGYW and FSW retention in 
Kenya4. For lower-risk women retained in the PrEP program, it was assumed that PrEP adherence was 
the same as the higher-risk group.  
To obtain a spectrum of HIV risk faced by both populations reflective of the sub-Saharan African 
settings, we simulated across the parameter ranges set out in Supplementary Materials: Methods – 
Table S2, yielding 7,920,000 distinct parameter sets.  
 
 
2.0 Population level – country case studies 
We modify the risk equations (S1.1) and (S1.2) to consider HIV risk and the scale-up of PrEP at a 
population rather than individual level.  
The total population size of high-risk women of type 𝑗𝑗 is 𝑁𝑁𝑖𝑖, in which the prevalence of HIV is 𝑝𝑝𝑖𝑖 . 
The coverage of PrEP in the population is 𝜔𝜔𝑖𝑖.  
In the process of parameterising the model to specific high-risk women populations, we develop the 
risk equations to also account for population-specific STI levels, levels of viral load suppression due 
to ART in HIV positive partners and male circumcision.  
The parameter 𝑠𝑠𝑖𝑖𝑖𝑖 is the probability that at least one person in the partnership between high risk 
woman from population 𝑗𝑗 and partner from population 𝑖𝑖 has an STI and 𝛿𝛿 is the multiplicative 
increase in per sex act probability of HIV transmission in the presence of an STI.  
Parameter 𝜗𝜗𝑖𝑖 is the proportion of HIV+ partners from population 𝑖𝑖 that are virally suppressed on ART 
and 𝜚𝜚 models the average reduction in the probability of HIV transmission due to viral suppression on 
ART. The parameter 𝜏𝜏𝑖𝑖 is the proportion of male partner population 𝑖𝑖 that are circumcised and 𝜎𝜎 is the 
average reduction in probability HIV transmission to women, when the male partner has been 
circumcised.   
Where high-risk women from population 𝑗𝑗 have partners drawn from a single male population, their 
HIV risk for a 12-month period is in the absence of PrEP is given by (leaving the j denotation to 
improve readability): 
Π(0) = 1 − �𝑝𝑝(𝜓𝜓(1−𝜏𝜏),0 + 𝜓𝜓𝜏𝜏,0) + (1 − 𝑝𝑝)�
𝐶𝐶   
Where: 
𝜓𝜓(1−𝜏𝜏),0 = (1 − 𝜏𝜏)�(1 − 𝜗𝜗)𝑠𝑠( 1 − 𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1− 𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛
+ 𝜗𝜗(1 − 𝑠𝑠)( 1− (1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
𝜓𝜓𝜏𝜏,0 = 𝜏𝜏�(1 − 𝜗𝜗)𝑠𝑠( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿)𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − (1 − 𝜎𝜎)𝛿𝛿)𝑛𝑛
+ 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛 + 𝜗𝜗(1 − 𝑠𝑠)( 1− (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
and 𝛿𝛿 = 𝛽𝛽𝑓𝑓(1− 𝜀𝜀𝛾𝛾) 
(S2.1) 
For women on PrEP we have 





𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼 = (1 − 𝜏𝜏)�(1 − 𝜗𝜗)𝑠𝑠( 1 − 𝛿𝛿𝛿𝛿)
𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1 − 𝛿𝛿)𝑛𝑛 + 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛
+ 𝜗𝜗(1 − 𝑠𝑠)( 1− (1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼 = 𝜏𝜏�(1 − 𝜗𝜗)𝑠𝑠( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿)
𝑛𝑛 + (1 − 𝜗𝜗)(1 − 𝑠𝑠)( 1− (1 − 𝜎𝜎)𝛿𝛿)𝑛𝑛
+ 𝜗𝜗𝑠𝑠( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿)𝑛𝑛 + 𝜗𝜗(1 − 𝑠𝑠)( 1− (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿)𝑛𝑛� 
and 𝛿𝛿 = 𝛽𝛽𝑓𝑓(1− 𝑟𝑟𝜃𝜃𝛼𝛼)(1− 𝜀𝜀𝛾𝛾) 
(S2.2) 
Similarly, when high-risk women from population 𝑗𝑗 have partners drawn from two male populations 
𝑖𝑖 = 1, 2, their HIV risk for a 12-month period is in the absence of PrEP is given by 
Π(0) = 1 − �𝑝𝑝1(𝜓𝜓(1−𝜏𝜏),0
1 + 𝜓𝜓𝜏𝜏,01 ) + (1 − 𝑝𝑝1)�
𝐶𝐶1�𝑝𝑝2(𝜓𝜓(1−𝜏𝜏),0




1 = (1 − 𝜏𝜏1)�(1− 𝜗𝜗1)𝑠𝑠1( 1 − 𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1− 𝛿𝛿1)𝑛𝑛1
+ 𝜗𝜗1𝑠𝑠1( 1− (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1− 𝑠𝑠1)( 1− (1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝜓𝜓𝜏𝜏,01 = 𝜏𝜏1�(1 − 𝜗𝜗1)𝑠𝑠1( 1− (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1− 𝑠𝑠1)( 1 − (1 − 𝜎𝜎)𝛿𝛿1)𝑛𝑛1
+ 𝜗𝜗1𝑠𝑠1( 1− (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1− 𝑠𝑠1)( 1− (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝛿𝛿1 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾1) 
and 
𝜓𝜓(1−𝜏𝜏),0
2 = (1 − 𝜏𝜏2)�(1− 𝜗𝜗2)𝑠𝑠2( 1− 𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1− 𝑠𝑠2)( 1− 𝛿𝛿2)𝑛𝑛2
+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1− 𝑠𝑠2)( 1 − (1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝜓𝜓𝜏𝜏,02 = 𝜏𝜏2�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1 − 𝑠𝑠2)( 1− (1 − 𝜎𝜎)𝛿𝛿2)𝑛𝑛2
+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1− 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝛿𝛿2 = 𝛽𝛽𝑓𝑓(1 − 𝜀𝜀𝛾𝛾2) 
(S2.3) 
When enrolled on a PrEP program: 
Π(𝑟𝑟𝜃𝜃𝛼𝛼) = 1 − �𝑝𝑝1(𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼
1 + 𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼
1 ) + (1 − 𝑝𝑝1)�
𝐶𝐶1�𝑝𝑝2(𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼
2 + 𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼




1 = (1 − 𝜏𝜏1)�(1 − 𝜗𝜗1)𝑠𝑠1( 1− 𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1− 𝑠𝑠1)( 1 − 𝛿𝛿1)𝑛𝑛1
+ 𝜗𝜗1𝑠𝑠1( 1− (1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1− 𝑠𝑠1)( 1− (1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝜓𝜓𝜏𝜏, 𝑟𝑟𝜃𝜃𝛼𝛼
1 = 𝜏𝜏1�(1− 𝜗𝜗1)𝑠𝑠1( 1 − (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + (1 − 𝜗𝜗1)(1 − 𝑠𝑠1)( 1− (1 − 𝜎𝜎)𝛿𝛿1)𝑛𝑛1
+ 𝜗𝜗1𝑠𝑠1( 1− (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿1)𝑛𝑛1 + 𝜗𝜗1(1− 𝑠𝑠1)( 1− (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿1)𝑛𝑛1� 
𝛿𝛿1 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1 − 𝜀𝜀𝛾𝛾1) 
And 
𝜓𝜓(1−𝜏𝜏), 𝑟𝑟𝜃𝜃𝛼𝛼
2 = (1 − 𝜏𝜏2)�(1 − 𝜗𝜗2)𝑠𝑠2( 1 − 𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1− 𝑠𝑠2)( 1− 𝛿𝛿2)𝑛𝑛2




2 = 𝜏𝜏2�(1− 𝜗𝜗2)𝑠𝑠2( 1− (1 − 𝜎𝜎)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + (1 − 𝜗𝜗2)(1− 𝑠𝑠2)( 1− (1 − 𝜎𝜎)𝛿𝛿2)𝑛𝑛2
+ 𝜗𝜗2𝑠𝑠2( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿𝛿𝛿2)𝑛𝑛2 + 𝜗𝜗2(1− 𝑠𝑠2)( 1 − (1 − 𝜎𝜎)(1 − 𝜚𝜚)𝛿𝛿2)𝑛𝑛2� 
𝛿𝛿2 = 𝛽𝛽𝑓𝑓(1 − 𝑟𝑟𝜃𝜃𝛼𝛼)(1− 𝜀𝜀𝛾𝛾2) 
(S2.4) 
All models were programmed in R version 3.3.29. 
 
2.1 Country case studies 
We apply the models to South Africa, Zimbabwe and Kenya, which are have generalised high 
prevalence HIV epidemics.10–13 These countries were chosen as case studies as they span a range of 
HIV burden levels in the region, they have each have adopted a national PrEP strategy,14,15,16 and been 
at the forefront of PrEP roll-out in sub-Saharan Africa17. 
In each country, we consider four groups of women at high risk of HIV through heterosexual 
transmission2,10,11,12: 𝑗𝑗 = {FSW, adolescent girls and young women aged 15-24 years (AGYW), 
women 25-34 years and women 35-49 years}. 
FSW are assumed to have partners drawn from two populations: regular partners and clients. AGYW 
are assumed to have partners drawn from their own age group and also the 25-34 years age group, 
given that 17% and 14% women 15-19 years report relationships with men at least 10 years older in 
Zimbabwe18 and Kenya19 respectively, and 36% South African women 15-19 years report 
relationships with men at least 5 years older.10 Women 25-34 years and women 35-49 years are 
assumed to have partners drawn from their own age groups.  
 
Data ranges to parameterise the models of HIV risk for each high-risk female group were drawn from 
the latest available in the literature and fitted to the latest national estimates of HIV incidence by 
group (see Supplementary Materials: Methods: Table S2) using Latin Hypercube Sampling (R PSE 
Package20) to yield at least 200 sets of parameter fits for each high-risk woman population modelled. 
 
2.2 Assessment of cost-effectiveness of scaling-up PrEP 
Given the significantly higher individual HIV risk faced by FSW,2 a priority group for PrEP roll-out 
in these settings,14,15,16 we assumed FSW as the benchmark for assessment of cost-effectiveness.  
Let $𝑌𝑌𝑖𝑖 be the unit cost per high risk woman from population 𝑗𝑗 ≠ 𝐹𝐹𝐹𝐹𝐹𝐹 retained in a PrEP program for 
population 𝑗𝑗, with 12-month retention level 𝑟𝑟𝑖𝑖, and $𝑌𝑌𝐹𝐹𝐹𝐹𝐹𝐹 the equivalent unit cost for a FSW PrEP 
program per FSW retained with 12-month retention level 𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹. 






A PrEP program for high risk population 𝑗𝑗 ≠ 𝐹𝐹𝐹𝐹𝐹𝐹 will then be equally as cost-effective per infection 










To determine the coverage, 𝜔𝜔𝑖𝑖, of PrEP in high-risk woman population 𝑗𝑗 ≠ 𝐹𝐹𝐹𝐹𝐹𝐹 needed to achieve 
the same risk reduction as coverage 𝜔𝜔𝐹𝐹𝐹𝐹𝐹𝐹 in FSW, we have: 













If PrEP were scaled up at equal coverage in both populations, then the relative number of infections 






This is equivalent to the relative total maximum number of infections averted per year if PrEP 
programs were scaled up to all HIV negative women in each population. 
 
For each $100𝑘𝑘 available for PrEP programming for each population, the estimated number of 
infections averted a year in each population would be:  
In high-risk women 𝑗𝑗 ≠ 𝐹𝐹𝐹𝐹𝐹𝐹 
 $100𝑘𝑘
$𝑌𝑌𝑗𝑗
(Π𝑖𝑖(0) − Π𝑖𝑖(𝑟𝑟𝑖𝑖𝜃𝜃𝛼𝛼𝑗𝑗)), 





The proportion of the potential total number of infections that could be averted a year in each 
population with $100𝑘𝑘 is: 














Estimating costs of PrEP to each high-risk group of women 
We estimated the costs of offering PrEP to each high-risk group of women. FSW were assumed to be 
offered PrEP through programmes with outreach and community mobilisation components. All other 
women were assumed to be offered PrEP through sexual and reproductive health services, with 
services for AGYW having larger counselling components. We reviewed cost data from 
demonstration projects and previous PrEP costing publications in Kenya21,22 and South Africa.3 We 
disaggregated cost estimates into service delivery and drug costs. For our calculations, we replaced 
reported drug costs by a range of USD57-80 per year. The lower bound is the internationally traded 
value of USD3.75 with a 25% top up of freight and distribution costs in country (15% shipping and 
handling charges, and 10% for drug distribution costs).23 The high bound is the highest reported price 
for drugs in the demonstration projects - 30 days TDF/FTC at USD6.75. For Zimbabwe, in addition to 
drug costs, we transferred non-tradable components of South African estimates using purchasing 
power parities24 following standard methods.25 In each case, the costs per person retained at 12-
months account for costs associated with drop out of individuals from the same population group 
enrolled but not retained in PrEP programs by month 12, consistent with previous studies.3,21,22 We 
adjusted all previously published costs to USD 2017.26  The amounts and detailed assumptions 





Table of Estimated Unit Costs for High-Risk Women Populations in South Africa, Zimbabwe and Kenya 
Country Population  










South Africa FSW 190 – 210 130 57 - 80 Unit costs measured during a demonstration project in Johannesburg and 
Pretoria via FSW clinics. Costs reported by Eakle et al3 included direct costs 
(eg, antiretrovirals, laboratory tests and consumables, labour and equipment) 
and indirect costs (eg, management, utilities, and transportation). We allocated 
outreach, demand creation and HCT costs to a unit cost of per person-year on 
PrEP as these were reported separately. 
South Africa AGYW (15-24y) 149 – 169 89 57 - 80 Unit costs estimated from local data and with input from several demonstration 
projects in South Africa. Costs reported by Meyer-Rath et al27 included direct 
costs (eg, antiretrovirals, laboratory tests and consumables, labour and 
equipment), indirect costs (eg, management, utilities, and transportation), and 
outreach, demand creation and HCT costs. These estimates reflect the authors’ 
estimation of costs among female adolescents. 
South Africa Women (25-34y) 128 – 148 68 57 - 80 Unit costs estimated from local data and with input from several demonstration 
projects in South Africa. Costs reported by Meyer-Rath et al27 included direct 
costs (eg, antiretrovirals, laboratory tests and consumables, labour and 
equipment), indirect costs (eg, management, utilities, and transportation), and 
outreach, demand creation and HCT costs. These estimates reflect the authors’ 
estimation of costs among young women. 
South Africa Women (35-49y) 87 – 107 27 57 - 80 Unit costs estimated from local data and with input from several demonstration 
projects in South Africa. Costs reported by Meyer-Rath et al27 included direct 
costs (eg, antiretrovirals, laboratory tests and consumables, labour and 
equipment), indirect costs (eg, management, utilities, and transportation), and 
outreach, demand creation and HCT costs. These estimates reflect the authors 
estimation of costs among pregnant women - we assumed for this lowest risk 
population, the cost will be similar to those attending ANC. 
Zimbabwe FSW 293 – 317 237 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.28 
Zimbabwe AGYW (15-24y) 219 – 243 163 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.28 
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Zimbabwe Women (25-34y) 181 - 204 124 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.28 
Zimbabwe Women (35-49y) 106 - 130 50 57 - 80 Drug costs were kept constant and we adjusted service costs in South Africa 
using PPP index.28 
      
Kenya FSW 399 - 423 343 57 - 80 Unit costs measured in preparation for a demonstration project in Nairobi via 
SWOP clinics (for FSW). Costs reported by Cremin et al21 included direct 
costs (eg, antiretrovirals, laboratory tests and consumables, labour and 
equipment), related costs (eg, outreach and demand creation), and indirect 
costs (eg, management, utilities, and transportation).  
Kenya AGYW (15-24y) 358 - 382 302 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al22 included fixed (start-up costs, 
such as microplanning and training, capital, overheads (e.g. building costs, 
transportation, and airtime) and administrative and supervisory personnel) or 
variable (drugs, clinical personnel direct service costs, laboratory testing, and 
other supplies). These estimates reflect the authors measurement of costs 
among the highest risk subpopulation in the general population. 
Kenya Women (25-34y) 294 - 318 238 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al22 included fixed (start-up costs, 
such as microplanning and training, capital, overheads (e.g. building costs, 
transportation, and airtime) and administrative and supervisory personnel) or 
variable (drugs, clinical personnel direct service costs, laboratory testing, and 
other supplies). These estimates reflect the authors measurement of costs 
among all women. 
Kenya Women (35-49y) 185 - 209 129 57 - 80 Unit costs measured as part of a demonstration project aiming to integrate 
PrEP into routine maternal and child health and family planning clinics in 
western Kenya. Costs reported by Roberts et al22 included fixed (start-up costs, 
such as microplanning and training, capital, overheads (e.g. building costs, 
transportation, and airtime) and administrative and supervisory personnel) or 
variable (drugs, clinical personnel direct service costs, laboratory testing, and 
other supplies). These estimates reflect the authors measurement of costs 
among all women excluding screening costs. 
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Table S1: Table of Estimated Unit Costs for High-Risk Women Populations in South Africa, Zimbabwe and Kenya. The estimated unit costs for FSW, AGYW, women 25-34 years and women 
35-49 years are shown disaggregated by the portion that is service delivery costs and the portion that is drug costs. The costs were calculated in line with the methodology set out in 
Supplementary Materials: Methods. The far right hand side column of the table sets out addition comments about specific assumptions made in calculating the data.  
*For our calculations, we replaced reported drug costs by a range of USD57-80. The low bound is the internationally traded value of USD3.75 
(https://www.theglobalfund.org/media/5813/ppm_arvreferencepricing_table_en.pdf) plus 25% top up of freight and distribution costs in country (15% shipping and handling charges, and 10% 
for drug distribution costs). The high bound is the highest reported price for drugs in the demonstration projects - 30 days TDF/FTC at USD6.75. 
**transferability of costs between countries followed standard guidelines (https://pdfs.semanticscholar.org/36ab/74fd24fb883db703c475364c34ad574a3f35.pdf) 





Model calibration  
The data used in the parameterisation and fitting of the models for all 3 country case studies shown in Table S2.  
Parameter Symbol 







Epidemic parameters        
FSW: HIV incidence, per 100 
person years 














on population size 
and proportion 
HIV-  
7.2 (4.5-9.8) CAPRISSA 002 200833 
AGYW: HIV incidence, per 
100 person years 
𝑖𝑖𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 
 






2016 estimates35  1.51 (1.31-1.71) National estimates, 
201736 
Women 25-34 years: HIV 
incidence, per 100 person 
years 






2016 estimates35 1.045 (0.87-
1.22) 
2017 estimates37. Low 
and High are min and 
max across all ages 
within range.  
Women 35-49 years: HIV 








2016 estimates35 0.665 (0.49-
0.84) 
2017 estimates37. Low 
and High are min and 
max across all ages 
within range.  
FSW: Population size, in 
1,000s of women 
𝑁𝑁𝐹𝐹𝐹𝐹𝐹𝐹 134 2013 size 
estimation38 
45 2017 estimates32 138 2013 size estimation39 
AGYW: Population size, in 
1,000s of women 
𝑁𝑁𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 4,067 2009 census40 1,304 2012 census41 4,901 2018 mid-year 
estimates42 
Women 25-34 years: 
Population size, in 1,000s of 
women 
𝑁𝑁𝐹𝐹25−34 2,935 2009 census40 1,089 2012 census41 5,366 2018 mid-year 
estimates42 
Women 34-49 years: 
Population size, in 1,000s of 
women  
𝑁𝑁𝐹𝐹35−49 2,374 2009 census40 817 2012 census41 5,354 2018 mid-year 
estimates42 








Long distance truck 
drivers, 200544 
0.339 (0.275 – 
0.410) 
Non-residents (study 














49 years), 201712  
Estimate is mid-
point. 
work), men, from 
KwaZulu-Natal, South 
Africa, 2004.45 
Men in general population 15-
49 years: HIV prevalence 
𝑠𝑠𝑝𝑝𝑀𝑀15−49 0.045 (0.0448-
0.0451) 
0.045 Males 15-49, 
201712.  
0.044 (0.036-0.052) 
males 15-64 years, 
KAIS, 201246. Use 
KAIS estimates as 
consistent with 
estimates used for 
individual age 
ranges below. No 
CI for 2017 
estimate, but fits 








on population size41 








KAIS, 201246 0.030 (0.0297-
0.03030) 
2016 estimates35 




on population size41 
0.039 (0.014 – 
0.06) 
AIDSInfo 201734 




KAIS, 201246 0.060 (0.0595-
0.0605) 
2016 estimates35 




on population size41 
0.124-0.184 Min and max of 5-year 
age categories (full 
national results not yet 
released). National 
estimates, 201736 









95% CI estimated 
assuming 
binomially 
0.224-0.248 Min and max of 5-year 
age categories (full 












on population size41 
released). National 
estimates, 201736 





















South Africa, 2014.47 
Estimate is 
midpoint.0.10 
AGYW: HIV prevalence 𝑝𝑝𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 0.03 (0.022-0.
038) 
KAIS, 201246 0.059 (0.0586-
0.0594) 
2016 estimates35 0.102 (0.046–
0.148) 
AIDSInfo 201734 




KAIS, 201246 0.182 (0.1813-
0.1827) 
2016 estimates35 0.275-0.347 Min and max of 5-year 
age categories (full 
national results not yet 
released). National 
estimates, 201736 








2016 estimates35 0.303-0.394 Min and max of 5-year 
age categories (full 
national results not yet 
released). National 
estimates, 201736 
Behavioural parameters        
FSW: number of client 
partners/ year 
𝐶𝐶𝑐𝑐_𝐹𝐹𝐹𝐹𝐹𝐹 320 (276-364) Monthly liaisons 




Median number in 




360 (234-486) Across studies49,50 
Estimate is 
midpoint. 
424 (312 – 504) Mean monthly reported 
number of clients per 
FSW, multiplied by 
12.51 
FSW: number of regular 
partners from male population 
15-49 years/ year 
𝐶𝐶𝑀𝑀15−49_𝐹𝐹𝐹𝐹𝐹𝐹 (1-4) Nairobi, 201048 2.0 (0.74-4.0) Imputed from South 
Africa, due to lack 
of data. Number of 
2.0 (0.74-4.0) Number of main sexual 
partners per 6 months, 
















partners per 6 
months, multiplied 
by 2.52 
FSW: number of sex acts per 
client/ year 






1 (1-1.2) Imputed from South 
Africa, due to lack 
of data. Number of 
sexual encounters 
per client.53 
1 (1-1.2) Number of sexual 
encounters per client.53 
FSW: number of sex acts with 
regular partners/ year 
𝑛𝑛𝑀𝑀15−49_𝐹𝐹𝐹𝐹𝐹𝐹 96 (48-144) Imputed from South 
Africa, due to lack 
of data. 
96 (48-144) Imputed from South 
Africa, due to lack 
of data.  
96 (48-144) Mean monthly 
frequency of sex acts in 
main partnerships, 
multiplied by 12.51 
FSW: average condom 




















South Africa, 2014.47 
FSW: average condom 


















South Africa, with non-
paying partner, 2014.47 
FSW: probability at least 1 
person in partnership has an 












0.21 (0.15-0.30) Low: Prevalence of 
Chlamydia trachomatis 
& Neisseria 
gonorrhoea in Hillbrow 
FSW.53  












FSW: probability at least 1 
person in partnership has an 












0.21 (0.15-0.30) Low: Prevalence of 
Chlamydia trachomatis 
& Neisseria 
gonorrhoea in Hillbrow 
FSW.53  
High: FSW STI 
prevalence, Durban.33 
        
AGYW: number of male 
partners 15-24 years/ year 
𝐶𝐶𝑀𝑀15−24_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 (0-4) Estimated range, 
Women 15-24, 
201419, accounting 
for the  proportion 
who have never had 
sexual intercourse 
and mean lifetime 
partners. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
range was 
considered in the 
fitting process (0-
10). 
(0-4) Estimated range, 
Women 15-24, 
201518, accounting 
for the  proportion 
who have never had 
sexual intercourse 
and mean lifetime 
partners. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
range was 
considered in the 
fitting process (0-
10). 
(0-4) Estimated range, 
Women 15-24, 201658, 
accounting for the  
proportion who have 
never had sexual 
intercourse and mean 
lifetime partners. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter range 
was considered in the 
fitting process (0-10). 
AGYW: number of male 
partners 25-34 years/ year 
𝐶𝐶𝑀𝑀25−34_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 (0-4) Estimated range, 
Women 15-24, 
201419, accounting 
for the proportion 
of age-discordant 
relationship. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
range was 
(0-4) Estimated range, 
Women 15-24, 
201518, accounting 
for the proportion 
of age-discordant 
relationship. 
Point estimate not 
deducible as 
categorical data. A 
wider parameter 
range was 
(0-4) Estimated range, 
Women 15-24, 201658, 




Point estimate not 
deducible as 
categorical data. A 











considered in the 
fitting process (0-
10). 
considered in the 
fitting process (0-
10). 
was considered in the 
fitting process (0-10). 
AGYW: number of sex acts 
male partners 15-24 years/ 
year 
𝑛𝑛𝑀𝑀15−24_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 182 (156-208) Imputed based on 
South Africa, due to 
lack of data 
82 (156-208) Imputed based on 
South Africa, due to 
lack of data 
182 (156-208) 3-4 a week x 52, youth, 
with regular partner, 
200059 Estimate is mid-
point. 
AGYW: number of sex acts 
male partners 24-34 years / 
year 
𝑛𝑛𝑀𝑀25−34_𝐴𝐴𝐴𝐴𝑌𝑌𝐹𝐹 48 (36-60) Imputed based on 
South Africa, due to 
lack of data 
48 (36-60) Imputed based on 
South Africa, due to 
lack of data 
48 (36-60) 3 sex acts a month, 
youth, non-spousal 
partner, 200059 
5 sex acts a month x12, 
married 18-20 year old, 
average number sex 
acts per short term 
partner formation, 
201660 
Estimate is mid-point 
AGYW: average condom 




Condom use at last 
sexual encounter 
with partner of 
unknown status61 








% who had 
intercourse in the 




arm, did not use 










0.498, 0.677. Females, 
males. 15-24 years, 
condom use at last sex, 
2017. 10 
Estimate is mid-point. 
AGYW: average condom 




Condom use at last 
sexual encounter 
with partner of 
unknown status61 




Females aged <25, 
males aged 25+, 
200564  
Never married 
women, % who 
0.504 (0.473-
0.534) 
0.473 females 15-24 
years, condom use last 
sex, those with more 
than 1 partner in the 
last year, 2017.10 












years,  201263 
Estimate is mid-
point. 




AGYW: probability at least 1 
person in partnership has an 
STI – with male partners 15-
24 years 

















gonorrhoea in 15-24 
year old males and 
females 
AGYW: probability at least 1 
person in partnership has an 
STI – with male partners 25-
34 years 
















25-49 year olds, 201065 
(greater than 15-24 
years estimate above) 
        
Women 25-34 years: number 
of male partners 25-34 years/ 
year 









point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
1.96 (0.92-3.0) Total partnerships 
in last 12 months 









point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
2.02 (1.03–3.0) Total partnerships in 
last 12 months reported 
by adult women, 
200666  
Estimated upper bound, 
Women 25-29 and 30-
39, accounting for 
mean lifetime partners, 
201658 
Estimate is mid-point. 
A wider parameter 
range was considered 












Women 25-34 years: number 
of sex acts male partners 24-
34 years / year 
𝑛𝑛𝑀𝑀25−34_𝐹𝐹25−3  93 (54-132) Average number of 
sex acts per partner 




imputed from South 




96 (60-132) Imputed from South 
Africa due to lack 
of data 
96 (60-132) Mean 5 sex acts a 
month x 12, 18-40 year 
old women, KwaZulu-
Natal, 201068 
2.54 mean sex acts a 
week x52, women, 
200769 
Estimate is mid-point. 
Women 25-34 years: average 
condom consistency with male 
partners 25-34 years 














Females ages 25+, 
males aged 25+, 
200564  




partners in last 12 
months, max(25-29 






Condom use at last sex, 
25-49 years, 201270 
Women 25-34 years: 
probability at least 1 person in 
partnership has an STI – with 
male partners 25-34 years 
















25-49 year olds, 201065 
For model structural 
sensitivity analysis: 
Women 25-34 years: number 
of male partners 35-49 years/ 
year 
𝐶𝐶𝑀𝑀35−49_𝐹𝐹25−3  50% of  
𝐶𝐶𝑀𝑀35−49_𝐹𝐹35−49 
As below 50% of  
𝐶𝐶𝑀𝑀35−49_𝐹𝐹35−49 













For model structural 
sensitivity analysis: 
Women 25-34 years: number 
of sex acts male partners 35-
49 years / year 
𝑛𝑛𝑀𝑀35−49_𝐹𝐹25−3  𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−49  As below 𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−49 As below 𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−49 As below 
For model structural 
sensitivity analysis: 
Women 25-34 years: average 
condom consistency with male 
partners 35-49 years 
𝛾𝛾𝑀𝑀35−49_𝐹𝐹25−3  𝛾𝛾𝑀𝑀25−34_𝐹𝐹25−34 
(same 
parameter 
value as  
𝛾𝛾𝑀𝑀35−49_𝐹𝐹35−49) 






As above  𝛾𝛾𝑀𝑀25−34_𝐹𝐹25−34 
(same parameter 
value as  
𝛾𝛾𝑀𝑀35−49_𝐹𝐹35−49) 
As above  
For model structural 
sensitivity analysis: 
Women 25-34 years: 
probability at least 1 person in 
partnership has an STI – with 




value as  
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−49
) 
As above  𝑠𝑠𝑀𝑀25−34_𝐹𝐹25−34
(same 
parameter 
value as  
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−49
) 
As above  𝑠𝑠𝑀𝑀25−34_𝐹𝐹25−34(
same parameter 
value as  
𝑠𝑠𝑀𝑀35−49_𝐹𝐹35−49) 
As above  
        
Women 35-49 years: number 
of male partners 35-49 years/ 
year 









point. A wider 
parameter range 
was considered in 
the fitting process 
(0-10). 
1.96 (0.92-3.0) Total partnerships 
in last 12 months 
reported by adult 
women, 200566 (no 








partners,  201518 
Estimate is mid-
point. A wider 
parameter range 
was considered in 
2.02 (1.03–3.0) Total partnerships in 
last 12 months reported 
by adult women, 
200666  
Estimated upper bound, 
Women 30-39, 40-49, 
accounting for mean 
lifetime partners, 
201658 
Estimate is mid-point. 
A wider parameter 
range was considered 












the fitting process 
(0-10). 
Women 35-49 years: number 
of sex acts male partners 35-
49 years / year 
𝑛𝑛𝑀𝑀35−49_𝐹𝐹35−4  93 (54-132) Average number of 
sex acts per partner 




imputed from South 




96 (60-132) Imputed from South 
Africa due to lack 
of data 
96 (60-132) Mean 5 sex acts a 
month x 12, 18-40 year 
old women, KwaZulu-
Natal, 201068 
2.54 mean sex acts a 
week x52, women, 
200769 
Estimate is mid-point. 
Women 35-49 years: average 
condom consistency with male 
partners 35-49 years 














Females ages 25+, 
males aged 25+, 
200564  




partners in last 12 
months, max(30-






Condom use at last sex, 
25-49 years, 201270 
 
Women 35-49 years: 
probability at least 1 person in 
partnership has an STI – with 
male partners 35-49 years 
















25-49 year olds, 201065 











Clients of FSW: proportion of 




All ages, not 
disaggregated by 
sex (only data 
available), 201771. 
Low and high 
values not reliably 
calculable 
binomially, as 
calculated based on 
ART cascade with 
unknown range at 
higher cascade 
levels, so taking 
low and high to be 
+/-10% of point 






Low and high 
values not reliably 
calculable 
binomially, as 
calculated based on 
ART cascade with 
unknown range at 
higher cascade 
levels, so taking 
low and high to be 
+/-10% of point 
estimate 
Same for below 
viral suppression 
data. 
0.508 (0.451 – 
0.564) 
Prevalence of viral load 
suppression, 15-49 
years, 2017.10 
Estimate is mid-point 
Men in general population 15-
49 years: proportion of HIV+ 
individuals virally supressed 
𝜗𝜗𝑀𝑀15−49 0.358 (0.3222-
0.3938) 
All ages, not 
disaggregated by 




2016 estimates35 0.508 (0.451 – 
0.564) 
Prevalence of viral load 
suppression, 2017.10 
Estimate is mid-point 
Men 15-24 years: proportion 




All ages, not 
disaggregated by 





2016 estimates35 0.491 (0.4419-
0.5401)  
Prevalence of viral load 
suppression, 2017.10 
Low and high values 
not reliably calculable 
binomially, as 
calculated based on 
ART cascade with 
unknown range at 
higher cascade levels, 
so taking low and high 












Same for below viral 
suppression data. 
Men 25-34 years: proportion 




All ages, not 
disaggregated by 




2016 estimates35 0.415 (0.3735-
0.4565) 
Prevalence of viral load 
suppression, 2017.10 
Men 35-49 years: proportion 




All ages, not 
disaggregated by 




2016 estimates35 0.522 (0.4698-
0.5742) 
Prevalence of viral load 
suppression, 35-44 
years, 2017.10 



















on population size41 
0.138 (0.1378-0.
1382) 
15-64 years, 2017.10 
95% CI estimated 
assuming binomially 
distributed, based on 
population size42 
Men in general population 15-

















15-64 years, 2017.10 
95% CI estimated 
assuming binomially 
distributed, based on 
population size42 



















95% CI estimated 
assuming binomially 
distributed, based on 
population size42 




























weighted average  
Estimate is 
weighted average 
distributed, based on 
population size42 
















35-44 years, 2017.10 
95% CI estimated 
assuming binomially 
distributed, based on 
population size42 
PrEP parameters        
FSW: average 12-month PrEP 
program retention  
𝑟𝑟𝐹𝐹𝐹𝐹𝐹𝐹     22% TAPS3 
FSW: average self-reported 
adherence 
𝛼𝛼𝐹𝐹𝐹𝐹𝐹𝐹     70-85% TAPS3 
FSW: HIV prevention-
effective PrEP adherence 
𝜃𝜃𝐹𝐹𝐹𝐹𝐹𝐹 Risk reduction of 0.79–0.99 
≥4 out 7 (≥ 57%) reported daily doses of PrEP a week 
Risk reduction of 0.73–1.06 
≥6 out 7 (≥ 86%) reported daily doses of PrEP a week 
For self-reported adherence of 70-85%, assume risk 
reduction range spanning range of both risk reduction 
estimates: 0.73-0.99 
Partners Demonstration Project prevention-effective adherence 
analysis - females8 
        
Transmission Probabilities        
Per sex act probability of HIV 
transmission from a 
chronically infected female to 










As stated  Average reduction in probability HIV transmission 
on ART 







HIV risk-reduction efficacy of 
condoms 
𝜀𝜀 0.85 (0.8 - 0.9) With consistent 














Multiplicative increase in per 
sex act probability of HIV 
transmission in the presence 
of an STI 
𝛿𝛿 4 (2-6) Combined study 
effectiveness 
estimate across 







Average reduction in 
probability of HIV 
transmission to women, when 
the male partner has been 
circumcised  
𝜎𝜎𝑓𝑓 0.1 (0–0.2) Male circumcision; 





Table S2: Parameters and data sources used in the parameterisation and fitting of the models. Point estimates are stated first with lower and upper bounds 




Supplementary Materials: Supplementary Results 
 
Model calibration 




Figure S1: Model Fits to HIV Incidence Data for South Africa. The model outcomes across the parameter ranges 
simulated through latin hypercube sampling are show in blue. The black book-ended lines show the 95% confidence 
intervals around national HIV incidence estimates (HIV risk per year), and the model outcomes that fit within this range are 
considered to be fits to data. The model outcomes and fitting ranges are shown distinctly for the four high-risk women 
populations: female sex workers (FSW), adolescent girls and young women aged 15-24 years (AGYW), women aged 25-34 




Figure S2: Model Fits to HIV Incidence Data for Zimbabwe. The model outcomes across the parameter ranges simulated 
through latin hypercube sampling are show in orange. The black book-ended lines show the 95% confidence intervals 
around national HIV incidence estimates (HIV risk per year), and the model outcomes that fit within this range are 
considered to be fits to data. The model outcomes and fitting ranges are shown distinctly for the four high-risk women 
populations: female sex workers (FSW), adolescent girls and young women aged 15-24 years (AGYW), women aged 25-34 





Figure S3: Model Fits to HIV Incidence Data for Kenya. The model outcomes across the parameter ranges simulated 
through latin hypercube sampling are show in green. The black book-ended lines show the 95% confidence intervals around 
national HIV incidence estimates (HIV risk per year), and the model outcomes that fit within this range are considered to be 
fits to data. The model outcomes and fitting ranges are shown distinctly for the four high-risk women populations: female 
sex workers (FSW), adolescent girls and young women aged 15-24 years (AGYW), women aged 25-34 years and women 






Figure S4 illustrates the relative cost at which PrEP will be equally as cost-effective to scale-up in a 
lower-risk group as it will be in a high-risk group, in the case that HIV prevalence in the higher-risk 
women partner population is 20%. It is demonstrated in four scenarios: underlying HIV prevalence in 
the lower-risk women’s partner population of 5%, 10%, 15% and 20%. This figure corresponds to 
Figure 2 in the main text, which demonstrates that case that HIV prevalence in the higher-risk 
women’s partner population is 40%.  
 
 
Figure S4: Relative unit cost at which it is cost-effective to scale-up PrEP from a higher- to lower-risk women group. The 
heatmaps show the relative unit cost at which it is cost-effective to scale-up PrEP from a higher- to a lower-risk group. The 
relative unit cost at which PrEP is cost-effective is shown by the relative average condom use in the lower-risk group 
compared to the higher-risk group (x-axis), and the relative number of sex acts a month for women in the lower-risk group 
compared to the higher-risk group (y-axis). The unit cost of PrEP in the lower-risk group relative to the higher-risk group at 
which PrEP is equally cost-effective between the two groups is shown by colour, according to the colour key on the right-
hand side of the graph. A colour within the yellow spectrum denotes that the relative unit cost of PrEP in the lower-risk 
group relative to the higher-risk group has to be less than 1 for it to be equally as cost cost-effective. A colour within the 
green spectrum denotes that the relative unit cost of PrEP in the lower-risk group relative to the higher-risk group will be 
greater than 1 for it to be equally as cost cost-effective. The 4 heatmaps correspond respectively (left to right, top to bottom) 
to underlying partner HIV prevalence of 5%, 10%, 15% and 20% in the lower-risk group’s partner population and all of 
them corresponding to 20% HIV prevalence in the higher-risk women’s partner population. The heatmaps are calculated 
using equation (S1.5) from the Supplementary Materials: Methods, assuming that women’s partners are drawn from a single 
population each. The higher-risk group are assumed to have 12-month PrEP program retention levels of 22%3 and 
adherence levels of 70-85% (corresponding to a risk reduction of 73-99%8). The PrEP program retention levels for the 
lower-risk group were simulated between +/- 25% the retention of the higher-risk group.4 For those lower-risk women 
retained in the PrEP program, it was assumed that PrEP adherence was the same as the higher-risk group. 
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Comparison of the Maximum Unit Costs of PrEP in Lower-Risk Groups Relative to Unit Costs FSW to be Equally as Cost-Effective, with Estimates 
of Current Relative Unit Costs 
    High Risk Women Population 
Country Unit Cost Relative to FSWs AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
Maximum Relative Unit Cost to be Cost-Effective 23.3 % ( 13.3 % , 36.8 % ) 16.2 % ( 9.1 % , 26 % ) 10.5 % ( 5.7 % , 18 % ) 
Estimated Current Relative Unit Cost 79.6 % ( 72.4 % , 86.7 % ) 68.7 % ( 62.7 % , 75.8 % ) 48.3 % ( 42.4 % , 54.7 % ) 
Difference (relative to FSW Unit Cost)  -56.2 % ( -69.2 % , -40.4 % ) -52.2 % ( -62.5 % , -41.4 % ) -37.6 % ( -45.8 % , -28.7 % ) 
Difference (relative to own Unit Cost)  -70.8 % ( -83.4 % , -53.2 % ) -76.2 % ( -87.0 % , -62.6 % ) -78.4 % ( -88.1 % , -61.8 % ) 
Zimbabwe 
Maximum Relative Unit Cost to be Cost-Effective 7.1 % ( 2.7 % , 14.9 % ) 17.7 % ( 7.1 % , 31.2 % ) 11 % ( 5.5 % , 17.2 % ) 
Estimated Current Relative Unit Cost 75.6 % ( 70.8 % , 80.8 % ) 63 % ( 58 % , 67.7 % ) 38.8 % ( 34.1 % , 42.7 % ) 
Difference (relative to FSW Unit Cost)  -67.7 % ( -75.1 % , -60.1 % ) -44.6 % ( -58.3 % , -31.1 % ) -28.1 % ( -35.3 % , -18.7 % ) 
Difference (relative to own Unit Cost)  -90.4 % ( -96.5 % , -80.6 % ) -71.8 % ( -88.9 % , -50.8 % ) -72 % ( -86.1 % , -53.6 % ) 
Kenya 
Maximum Relative Unit Cost to be Cost-Effective 8.1 % ( 3.9 % , 18.5 % ) 9.1 % ( 3.6 % , 17.7 % ) 6.4 % ( 3.1 % , 11.6 % ) 
Estimated Current Relative Unit Cost 90.3 % ( 86.2 % , 94.8 % ) 74.9 % ( 71.1 % , 78.4 % ) 48.1 % ( 45.1 % , 51.6 % ) 
Difference (relative to FSW Unit Cost)  -81.5 % ( -89 % , -71 % ) -66 % ( -73.4 % , -57.5 % ) -41.7 % ( -46.4 % , -36.2 % ) 
Difference (relative to own Unit Cost)  -91 % ( -95.7 % , -79.6 % ) -88 % ( -95.3 % , -76.6 % ) -86.7 % ( -93.7 % , -75.4 % ) 
Table S3: Comparison of the Maximum Unit Costs of PrEP in Lower-Risk Groups Relative to Unit Costs FSW to be Equally as Cost-Effective, with Estimates of Current Relative Unit 
Costs. The table shows the maximum relative unit costs of PrEP in AGYW, women 25-34 years and women 35-49 years relative to the unit costs of PrEP for FSW, for PrEP to be equally as 
cost-effective (calculated using equation S1.5 in Supplementary Materials: Methods). It compares this to the estimated current relative unit costs between the populations, calculated using the 
data set out in Table S2. The table shows the difference between these two estimates (relative to the FSW unit cost of PrEP). It also shows what this difference represents relative to the group’s 
(i.e. AGYW, women 25-34 years or women 35-49 years) own unit cost, which is equivalent to the % the unit cost would have to drop for PrEP to be equally as cost-effective as for FSW. The 
comparisons are shown separately for South Africa, Zimbabwe and Kenya. The values shown in the table outside the brackets are the median values, and the values shown in the brackets are 






  Median relative Cost of Equal Coverage of PrEP between stated female population group and FSW 
Country AGYW Women 25-34 years Women 35-49 years 
South 
Africa 28.3 26.7 18.7 
Zimbabwe 21.9 15.2 7 
Kenya 27.4 16.4 8.5 
Table S4a: Median relative cost of equal coverage of PrEP between stated female population group and FSW. The table 
shows the median cost of equal coverage of PrEP between FSW, AGYW, women 25-34 years or women 35-49 years and 
FSW. It is calculated as (population size of female group*unit cost of PrEP for female group)/ (population size of FSW*unit 
cost of PrEP for FSW). The unit costs of PrEP for each high-risk woman group are as stated in Table S2. AGYW is used as 





Table S4 sets out the estimated number of infections that could be averted a year due to PrEP in each 
high-risk women population group, in each country, for every $100,000 available for PrEP 
programming, at the PrEP unit costs stated in Table S2. These data correspond to Figure 4 in the main 
text. 
 
For each $100k available for PrEP programming a year,  
the number of HIV infections that could be averted due to PrEP 
  High Risk Women Population 
Country FSW AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
5.7 ( 3.8 , 8.8 ) 1.7 ( 1.1 , 2.4 ) 1.3 ( 0.9 , 2 ) 1.2 ( 0.8 , 2 ) 
Zimbabwe 3.4 ( 2.9 , 4.1 ) 0.3 ( 0.1 , 0.7 ) 1 ( 0.4 , 1.8 ) 0.9 ( 0.5 , 1.6 ) 
Kenya 1.5 ( 0.9 , 2.4 ) 0.1 ( 0.1 , 0.3 ) 0.2 ( 0.1 , 0.3 ) 0.2 ( 0.1 , 0.3 ) 
Table S5: Median and 95% credible intervals (95% CrIs) of the relative number of infections that could be averted a year 
due to PrEP for each $100k available for PrEP programming. The table shows the median (value outside the brackets) and 
95% CrIs (inside the brackets) of the number of HIV infections that could be averted a year due to PrEP, for each $100k 
available for PrEP programming, for FSW, AGYW, women 25-34 years or women 35-49 years. The relative number of 
infections that could be averted is calculated using equation S2.10 from Supplementary Materials and assumes that 12-
month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for 
FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3 The unit costs of PrEP for each high-risk 
woman group are as stated in Table S2. AGYW is used as shorthand for adolescent girls and young women 15-24 years. 
 
In South Africa, $100,000 could avert a median 5.7 infections a year or 0.2% (95% CrI: 0.1%, 0.4%) 
of the total infections a year due to PrEP in FSW; median 1.7 infections a year or <0.1% (95% CrI: 
<0.1%, <0.1%) of the total infections a year in AGYW; mediaan 1.3 infections a year or <0.1% (95% 
CrI: <0.1%, <0.1%) of total infections a year in women 25-34 years; and median 1.2 infections a year 
or <0.1% (95% CrI: <0.1%, <0.1%) of total infections a year in women 35-49 years. This highlights, 
that to maximise cost-effectiveness on an individual basis, PrEP would be scaled-up first in FSW, 
then AGYW, then women 35-49 years, then women 25-34 years. 
In Zimbabwe, $100,000 could avert a median 3.4 infections a year or 0.3% (95% CrI: 0.3%, 0.4%) 
of the total infections a year due to PrEP in FSW; median 0.3 infections a year or <0.1% (95% CrI: 
<0.1%, <0.1%) of the total infections a year in AGYW; median 1.0 infections a year or <0.1% (95% 
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CrI: <0.1%, <0.1%) of total infections a year in women 25-34 years; and median 0.9 infections a year 
or <0.1% (95% CrI: <0.1%, <0.1%) of total infections a year in women 35-49 years. This highlights, 
that to maximise cost-effectiveness on an individual basis, PrEP would be scaled-up first in FSW, 
then women 25-34 years, then women 35-49 years, then AGYW. 
In Kenya, $100,000 could avert a median 1.5 infections a year or <0.1% (95% CrI: <0.1%, 0.1%) of 
the total infections a year due to PrEP in FSW; median 0.1 infections a year or <0.1% (95% CrI: 
<0.1%, <0.1%) of the total infections a year in AGYW; median 0.2 infections a year or <0.1% (95% 
CrI: <0.1%, <0.1%) of total infections a year in women 25-34 years; and median 0.2 infections a year 
or <0.1% (95% CrI: <0.1%, <0.1%) of total infections a year in women 35-49 years. This highlights, 
that to maximise cost-effectiveness on an individual basis, PrEP would be scaled-up first in FSW, 
then women 25-34 years and women 35-49 years, and then AGYW.  
 
 
Figure S5 shows, the proportion of the total number of HIV infections that could be averted a year for 
each $100k available for PrEP programming.. The corresponding data to the figure are set out in 
Table S5 below. 
 
Figure S5: Boxplot showing for each $100k available for PrEP programming, the proportion of the total number of HIV 
infections that could be averted a year with these funds. The boxplot shows for each $100k available for PrEP 
programming, the proportion of infections that could be averted a year with these funds for each of HIV negative FSW, 
AGYW, women 25-34 years or women 35-49 years. The proportion of total infections that could be averted a year are 
shown, grouped left to right, for FSW, AGYW, women 25-34 years and women 35-49 years. Within each age grouping, the 
results are show by country, left to right, for South Africa (in blue), Zimbabwe (in orange) and Kenya (in blue). The 
proportion of total infections that could be averted a year are calculated using equation S2.11 from Supplementary 
Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is 
within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3 The 
abbreviations used in the graph are as follows: AGYW denotes adolescent girls and young women 15-24 years, S Africa 
denotes South Africa and Zim denotes Zimbabwe. 
For each $100k available for PrEP programming,  
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the proportion of HIV infections that could be averted a year 
  High Risk Women Population 
Country FSW AGYW Women 25-34 years Women 35-49 years 
South 
Africa 
0.2 % ( 0.1 % , 0.4 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 
Zimbabwe 0.3 % ( 0.3 % , 0.4 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 
Kenya 0 % ( 0 % , 0.1 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 0 % ( 0 % , 0 % ) 
Table S6: Median and 95% credible intervals (95% CrIs) of the proportion of the total number of HIV infections that 
could be averted a year with each $100k available for PrEP programming. The table shows the median (value outside the 
brackets) and 95% CrIs (inside the brackets) of the proportion of the total number of HIV infections that could be averted a 
year with each $100k available for PrEP programming for FSW, AGYW, women 25-34 years or women 35-49 years. The 
proportion of the total number of HIV infections that could be averted is calculated using equation S2.11 from 
Supplementary Materials and assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-
49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration 
project.3 The unit costs of PrEP for each high-risk woman group are as stated in Table S2. AGYW is used as shorthand for 
adolescent girls and young women 15-24 years. 
 
Figure S6 sets out the number of HIV negative individuals in each high-risk woman population that 
would need to be enrolled on PrEP to avert the same number of infections as 10% PrEP program 
coverage in HIV negative FSW. The corresponding data to the figure are set out in Table S6. 
 
Figure S6: Number of HIV negative women needed to be enrolled on PrEP to avert the same number of infections as 
10% PrEP program coverage in HIV negative FSW. The violin plot shows number of HIV negative AGYW, women 25-34 
years or women 35-49 years in the population that would have to be enrolled in a PrEP program in order to achieve the 
same number of infections averted over 12 months as with 10% of the HIV negative FSW population enrolled in a PrEP 
program. As a comparison, the number of women represented by 10% of HIV negative FSW is shown in the far left hand 
side block of the figure. The number of HIV negative women needed to be enrolled on PrEP to avert the same number of 
infections as 10% PrEP program coverage in HIV negative FSW is then grouped left to right, for AGYW, women 25-34 
years or women 35-49 years. Within each age grouping, the results are show by country, left to right, for South Africa (in 
blue), Zimbabwe (in orange) and Kenya (in blue). In the violin plots, the white dots represent the median values, the thick 
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black vertical lines represent the interquartile range, the vertical length of the violin represents the range of values and the 
width of the violin represents the frequency with which those values occur. Where two horizontal grey lines are shown 
instead of a violin, it indicates that the range of values is limited in variation. The number of HIV negative women needed to 
be enrolled on PrEP to avert the same number of infections averted as 10% PrEP program coverage in HIV negative FSW is 
calculated using equation S2.7 from Supplementary Materials and assumes that 12-month PrEP program retention in 
AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels for FSW, taken to be 22%, in line 
with the results of the TAPS demonstration project.3 The abbreviations used in the graph are as follows: AGYW denotes 












Number of HIV negative women needed to be enrolled on PrEP  
to avert the same number of infections as 10% PrEP program coverage in HIV negative FSW 
  High Risk Women Population 
Country FSW (comparator) 





18531 (9594, 37052 ) 31798 (16411, 65199) 52240 (26287 , 111053) 
Zimbabwe 1933 (1910, 1953) 
27496 (12962, 72904) 14933 (8535, 37453) 36978 (23578, 73838) 







Table S7: Median and 95% credible interval (CrIs) of the number of HIV negative women needed to be enrolled on PrEP 
to avert the same number of infections as 10% PrEP program coverage in HIV negative FSW. The table shows the median 
(value outside the brackets) and 95% CrIs (inside the brackets) of the number of HIV negative AGYW, women 25-34 years 
or women 35-49 years in the population that would have to be enrolled in a PrEP program in order to achieve the same 
number of infections averted over 12 months as with 10% of the HIV negative FSW population enrolled in a PrEP program. 
As a comparison, the median and 95% CrIs of the numbers of women represented by 10% of HIV negative FSW is shown in 
the far left column of the table. The median and 95% CrIs of the numbers of HIV negative women needed to be enrolled on 
PrEP to avert the same number of infections as 10% PrEP program coverage in HIV negative FSW is then grouped left to 
right in the 2nd to 4th columns of the table, for AGYW, women 25-34 years or women 35-49 years respectively. Within each 
age grouping, the results are show by country, for South Africa, Zimbabwe and Kenya in rows 1 to 3 respectively. The 
number of HIV negative women needed to be enrolled on PrEP to avert the same number of infections averted as 10% PrEP 
program coverage in HIV negative FSW is calculated using equation S2.7 from Supplementary Materials and assumes that 
12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels 
for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3  
 
Figure S7 shows PrEP program coverage in HIV negative individuals in each high-risk woman 
population that would need to be enrolled on PrEP to avert the same number of infections as 10% 




Figure S7: Boxplot of the PrEP program coverage in HIV negative women needed to avert the same number of HIV 
infections as 10% coverage in HIV negative FSW. The boxplot shows the PrEP program coverage in HIV negative AGYW, 
women 25-34 years or women 35-49 years to avert the same number of infections as 10% program coverage in HIV negative 
FSW. The PrEP program coverage levels are shown, grouped left to right, for AGYW, women 25-34 years or women 35-49 
years. Within each age grouping, the results are show by country, left to right, for South Africa (in blue), Zimbabwe (in 
orange) and Kenya (in blue). The coverage levels are calculated using equation S2.7 from Supplementary Materials and 
assumes that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of 
retention levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3 The abbreviations 
used in the graph are as follows: AGYW denotes adolescent girls and young women 15-24 years, S Africa denotes South 
Africa and Zim denotes Zimbabwe. 
 
PrEP program coverage in HIV negative women to avert the same number of infections  
as 10% coverage in HIV negative FSW 
  High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South Africa 0.4 % ( 0.2 % , 0.8 % ) 0.7 % ( 0.4 % , 1.4 % ) 1.2 % ( 0.6 % , 2.5 % ) 
Zimbabwe 2.2 % ( 1.1 % , 5.9 % ) 1.2 % ( 0.7 % , 3.1 % ) 3 % ( 1.9 % , 6 % ) 
Kenya 2.9 % ( 1.3 % , 6.3 % ) 3.8 % ( 2 % , 9.7 % ) 6.9 % ( 3.8 % , 14.4 % ) 
Table S8: Median and 95% credible intervals (95% CrIs) of the PrEP program coverage in HIV negative women to avert 
the same number of infections as with 10% PrEP program coverage in HIV negative FSW. The table shows the median 
(value outside the brackets) and 95% CrIs (inside the brackets) of the PrEP program coverage in AGYW, women 25-34 
years or women 35-49 years to achieve the same number of infections a year as 10% PrEP program coverage in HIV 
negative FSW. The PrEP program coverage is calculated using equation S2.7 from Supplementary Materials and assumes 
that 12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention 
levels for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3 AGYW is used as shorthand for 
adolescent girls and young women 15-24 years. 
 
Table S8 shows the relative number of infections that could be averted a year with PrEP at equal 
coverage levels in AGYW, women 25-34 years and women 35-49 years as in FSW. These data 




Relative number of infections that could be averted a year on PrEP 
with equal program coverage as in FSW 
  High Risk Women Population 
Country AGYW  Women 25-34 years  Women 35-49 years 
South Africa 24 ( 12 , 45 ) 14 ( 7 , 27 ) 8 ( 4 , 17 ) 
Zimbabwe 4 ( 2 , 9 ) 8 ( 3 , 14 ) 3 ( 2 , 5 ) 
Kenya 3 ( 2 , 8 ) 3 ( 1 , 5 ) 1 ( 1 , 3 ) 
Table S9: Median and 95% credible intervals (95% CrIs) of the relative number of infections that could be averted a year 
on PrEP with equal program coverage as in FSW. The table shows the median (value outside the brackets) and 95% CrIs 
(inside the brackets) of the relative number of infections that could be averted a year on PrEP in AGYW, women 25-34 years 
or women 35-49 years relative to the number that could be averted in FSW with equal PrEP program coverage. The relative 
number of infections that could be averted is calculated using equation S2.9 from Supplementary Materials and assumes that 
12-month PrEP program retention in AGYW, women 25-34 years or women 35-49 years is within +/-25% of retention levels 
for FSW, taken to be 22%, in line with the results of the TAPS demonstration project.3 AGYW is used as shorthand for 






25% less PrEP-adherence-related HIV risk reduction across all women groups 
 
Table S9 shows the percentage change in the maximum unit cost at which PrEP will be equally cost-
effective in other high-risk women groups (AGYW, women 25-34 years and women 35-49 years) as 
in FSW, if 25% less PrEP-adherence-related HIV risk reduction were assumed across all women 
groups. These results are a comparison of the results set out in Table S3 (top row for each country) 
with what the results would be if the same analysis were repeated with 25% less PrEP-adherence-
related HIV risk reduction across all women groups. 
 
 
% Change in Maximum Unit Cost at which PrEP is equally as Cost-Effective as for FSW,  
with 25% reduced HIV risk-reduction across all Groups 
  High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South Africa 0.001% (0.000%, 0.003%) -0.002% (-0.002%, 0.000%) 0.000% (-0.002%, 0.000%) 
Zimbabwe 0.001% (-0.002%, 0.002%) -0.002% (-0.001%, 0.001%) -0.001% (-0.002%, -0.001%) 
Kenya 0.000% (0.000%, 0.001%) 0.001% (0.000%, 0.002%) 0.000% (0.000%, 0.000%) 
Table S10: Percentage change in the maximum unit cost at which PrEP will be equally cost-effective in other high-risk 
women groups (AGYW, women 25-34 years and women 35-49 years) as in FSW, if 25% less PrEP-adherence-related 
HIV risk reduction were assumed across all women groups. The table shows the percentage change in the maximum 
relative unit costs of PrEP in AGYW, women 25-34 years and women 35-49 years relative to the unit costs of PrEP for FSW, 
for PrEP to be equally as cost-effective (calculated using equation S1.5 in Supplementary Materials: Methods), if the PrEP-
adherence-associated HIV risk reduction were reduced by 25% compared to the baseline analysis presented in Table S3 (top 
row for each country). The comparisons are shown separately for South Africa, Zimbabwe and Kenya. AGYW is used as 
shorthand for adolescent girls and young women 15-24 years. The values shown in the table outside the brackets are the 
median values, and the values shown in the brackets are the 95% credible intervals (CrIs). All values are shown rounded to 
the nearest 3 decimal places. 
Table S10 sets out the percentage change in the in the relative number of infections averted a year on 
PrEP with equal coverage as with FSW, if 25% less PrEP-adherence-related HIV risk reduction were 
assumed across all women groups. These results are a comparison of the results set out in Table S8 
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with what the results would be if the same analysis were repeated with 25% less PrEP-adherence-
related HIV risk reduction across all women groups. 
 
 
% Change in Relative Number of Infections Averted a Year on PrEP with equal coverage as 
with FSW,  
with 25% reduced PrEP-adherence-related HIV-risk reduction across Groups 
  High Risk Women Population 
Country AGYW  Women 25-34 years  Women 35-49 years 
South 
Africa 0.000 % (-0.001% , 0.000 % ) -0.001 % ( -0.001% , -0.001%) -0.001 % ( -0.001 % , 0.000 % ) 
Zimbabwe 0.000% (-0.001 % , 0.002 %) -0.002% (-0.001 % , 0.001%) -0.001% (-0.002 % , -0.001 %) 
Kenya 0.000% (0.000% , 0.001 %) 0.001% (0.000% , 0.002%) 0.000% (0.000 % , 0.000 %) 
 
Table S11: Percentage change in the relative number of infections averted a year on PrEP with equal coverage as with 
FSW, with 25% reduced PrEP-adherence-related HIV-risk reduction across groups. The table shows the median (value 
outside the brackets) and 95% CrIs (inside the brackets) of the percentage change in the relative number of infections that 
could be averted a year on PrEP in AGYW, women 25-34 years or women 35-49 years relative to the number that could be 
averted in FSW with equal PrEP program coverage, if the PrEP-adherence-associated HIV risk reduction were reduced by 
25% compared to the baseline analysis presented in Table S8. For the underlying analyses, the relative number of infections 
that could be averted is calculated using equation S2.9 from Supplementary Materials. AGYW is used as shorthand for 
adolescent girls and young women 15-24 years. All values are shown rounded to the nearest 3 decimal places. 
 
 
25% less PrEP-adherence-related HIV risk reduction across all non-FSW women groups 
 
Table S11 sets out the percentage change in the maximum unit cost at which PrEP will be equally 
cost-effective in other high-risk women groups (AGYW, women 25-34 years and women 35-49 
years) as in FSW, if 25% less PrEP-adherence-related HIV risk reduction were assumed across all 
non-FSW women groups (i.e. AGYW, women 25-34 years and women 35-49 years). These results are 
a comparison of the results set out in Table S3 (top row for each country) with what the results would 
be if the same analysis were repeated with 25% less PrEP-adherence-related HIV risk reduction 
across all non-FSW women groups. 
 
 
% Change in Maximum Unit Cost at which PrEP is equally as Cost-Effective as for FSW,  
with 25% reduced HIV risk-reduction across all non-FSW women groups 
  High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South Africa 0.253 % (0.252 %, 0.252 %) 0.253 % (0.252 %, 0.252% ) 0.252 % (0.251%, 0.251%) 
Zimbabwe 0.254 % (0.253 %, 0.253 %) 0.253 % (0.253% ,0.254%) 0.252 % (0.252%,0.252%) 
Kenya 0.258 % (0.260 %, 0.256 %) 0.257 % (0.257%,0.258%) 0.256 % (0.255%,0.258%) 
Table S12: Percentage change in the maximum unit cost at which PrEP will be equally cost-effective in other high-risk 
women groups (AGYW, women 25-34 years and women 35-49 years) as in FSW, if 25% less PrEP-adherence-related 
HIV risk reduction were assumed across all non-FSW women groups (i.e. AGYW, women 25-34 years and women 35-49 
years). The table shows the percentage change in the maximum relative unit costs of PrEP in AGYW, women 25-34 years 
and women 35-49 years relative to the unit costs of PrEP for FSW, for PrEP to be equally as cost-effective (calculated using 
equation S1.5 in Supplementary Materials: Methods), if the PrEP-adherence-associated HIV risk reduction were reduced by 
25% for all non-FSW women groups compared to the baseline analysis presented in Table S3 (top row for each country). 
The comparisons are shown separately for South Africa, Zimbabwe and Kenya. AGYW is used as shorthand for adolescent 
girls and young women 15-24 years. The values shown in the table outside the brackets are the median values, and the 






Table S12 sets out the percentage change in the in the relative number of infections averted a year on 
PrEP with equal coverage as with FSW, if 25% less PrEP-adherence-related HIV risk reduction were 
assumed across all non-FSW women groups (i.e. AGYW, women 25-34 years and women 35-49 
years). These results are a comparison of the results set out in Table S8 with what the results would be 
if the same analysis were repeated with 25% less PrEP-adherence-related HIV risk reduction across 
all non-FSW women groups. 
 
 
% Change in Relative Number of Infections Averted a Year on PrEP with equal coverage as 
with FSW,  
with 25% reduced PrEP-adherence-related HIV-risk reduction across all non-FSW women 
groups 
  High Risk Women Population 
Country AGYW  Women 25-34 years  Women 35-49 years 
South 
Africa 0.252 % ( 0.250 % , 0.252 % ) 0.251 % ( 0.252 % , 0.252 % ) 0.252 % ( 0.251 % , 0.251 % ) 
Zimbabwe 0.253 % ( 0.254 % , 0.254 % ) 0.253 % ( 0.253 % , 0.254 % ) 0.252 % ( 0.252 % , 0.253 % ) 
Kenya 0.257 % ( 0.260 % , 0.256 % ) 0.26 % ( 0.257 % , 0.258 % ) 0.256 % ( 0.255 % , 0.258 % ) 
 
Table S13: Percentage change in the relative number of infections averted a year on PrEP with equal coverage as with 
FSW, with 25% reduced PrEP-adherence-related HIV-risk reduction across all non-FSW women groups (i.e. AGYW, 
women 25-34 years and women 35-49 years). The table shows the median (value outside the brackets) and 95% CrIs (inside 
the brackets) of the percentage change in the relative number of infections that could be averted a year on PrEP in AGYW, 
women 25-34 years or women 35-49 years relative to the number that could be averted in FSW with equal PrEP program 
coverage, if the PrEP-adherence-associated HIV risk reduction were reduced by 25% for all non-FSW women groups 
compared to the baseline analysis presented in Table S8. For the underlying analyses, the relative number of infections that 
could be averted is calculated using equation S2.9 from Supplementary Materials. AGYW is used as shorthand for 
adolescent girls and young women 15-24 years. All values are shown rounded to the nearest 3 decimal places. 
 
 
Structural sensitivity analysis: women 25-34 years have partners from males 35-49 years, in addition 
to 25-34 years 
 
Table S13 sets out the percentage change in the maximum unit cost at which PrEP will be equally 
cost-effective in other high-risk women groups (AGYW, women 25-34 years and women 35-49 
years) as in FSW, under the structural sensitivity analysis exploring the case that women 25-34 years 
draw partners from males 35-49 years, in addition to 25-34 years. These results are a comparison of 
the results set out in Table S3 (top row for each country) with what the results would be if the same 
analysis were repeated with women 25-34 years drawing partners from males 35-49 years, in addition 
to 25-34 years (assumed to be the only partner population, in Table S3). Whilst the structural 
sensitivity analysis directly affects the model outcomes for women 25-34 years, it also indirectly 
affects the mean and 95% CrI outcomes for FSW, AGYW and women 35-49 year through changes to 








% Change in Maximum Unit Cost at which PrEP is equally as Cost-Effective as for FSW,  
with women 25-34 years having partners drawn from 2 populations 
  High Risk Women Population 
Country AGYW Women 25-34 Women 35-49 years 
South 
Africa -0.017 % (-0.063%, 0.017%) -0.091% (-0.157%, -0.089%) 0.016% (-0.009%, 0.060%) 
Zimbabwe 0.003% (0.015%, 0.018%) -0.299% (-0.476%, -0.081%) 0.075% (-0.015%, 0.128%) 
Kenya 0.020% (-0.004%, 0.000%) -0.205% (-0.596%, 0.023%) 0.038% (0.030%, 0.059%) 
Table S14: Percentage change in the maximum unit cost at which PrEP will be equally cost-effective in other high-risk 
women groups (AGYW, women 25-34 years and women 35-49 years) as in FSW, under the structural sensitivity analysis 
exploring the case that women 25-34 years draw partners from males 35-49 years, in addition to 25-34 years. The table 
shows the percentage change in the maximum relative unit costs of PrEP in AGYW, women 25-34 years and women 35-49 
years relative to the unit costs of PrEP for FSW, for PrEP to be equally as cost-effective (calculated using equation S1.5 in 
Supplementary Materials: Methods), if women 25-34 years are assumed to draw partners from males 35-49 years, in 
addition to 25-34 years, compared to the baseline analysis presented in Table S3 (top row for each country). The 
comparisons are shown separately for South Africa, Zimbabwe and Kenya. AGYW is used as shorthand for adolescent girls 
and young women 15-24 years. The values shown in the table outside the brackets are the median values, and the values 
shown in the brackets are the 95% credible intervals (CrIs). All values are shown rounded to the nearest 3 decimal places. 
 
 
Table S14 sets out the percentage change in the in the relative number of infections averted a year on 
PrEP with equal coverage as with FSW, if women 25-34 years are assumed to draw partners from 
males 35-49 years, in addition to 25-34 years. These results are a comparison of the results set out in 
Table S8 with what the results would be if the same analysis were repeated with women 25-34 years 
drawing partners from males 35-49 years, in addition to 25-34 years (assumed to be the only partner 
population, in Table S8). Whilst the structural sensitivity analysis directly affects the model outcomes 
for women 25-34 years, it also indirectly affects the mean and 95% CrI outcomes for FSW, AGYW 




% Change in Relative Number of Infections Averted a Year on PrEP with equal coverage as 
with FSW,  
with women 25-34 years having partners drawn from 2 populations 
  High Risk Women Population 
Country AGYW  Women 25-34 years  Women 35-49 years 
South 
Africa 0.044 % (-0.091 %, -0.03 %) -0.024 % (-0.176 % , -0.12 %) 0.039 % (-0.054 %, 0.061 %) 
Zimbabwe 0.001 % (0.008 %, 0.015 %) -0.297 % (-0.483 %, -0.087 %) 0.064 % (-0.018 %, 0.125 %) 
Kenya 0.023 % (-0.004 %, -0.002 %) -0.223 % (-0.593 %, 0.023 %) 0.048 % (0.042 % , 0.074 %) 
 
Table S15: Percentage change in the relative number of infections averted a year on PrEP with equal coverage as with 
FSW, under the structural sensitivity analysis exploring the case that women 25-34 years draw partners from males 35-49 
years, in addition to 25-34 years. The table shows the median (value outside the brackets) and 95% CrIs (inside the 
brackets) of the percentage change in the relative number of infections that could be averted a year on PrEP in AGYW, 
women 25-34 years or women 35-49 years relative to the number that could be averted in FSW with equal PrEP program 
coverage, if women 25-34 years are assumed to draw partners from males 35-49 years, in addition to 25-34 years, 
compared to the baseline analysis presented in Table S8. For the underlying analyses, the relative number of infections that 
could be averted is calculated using equation S2.9 from Supplementary Materials. AGYW is used as shorthand for 
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